Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Arihant's

Arihant's Securities Limited

Premium
Information Technology

Arihant's Securities Limited is a Chennai-based, promoter-controlled, RBI-registered Base Layer NBFC. It was incorporated in 1994 and has been listed on BSE since the mid-1990s. Its constitutional objects cover loan financing, share trading, leasing, hire purchase and related financial services. In practice, however, it now works as a small proprietary investment holding company. Almost all of its ₹38.7 crore balance sheet (FY2026) sits in equity investments, of which ₹35.67 crore is carried at fair value through other comprehensive income (FVOCI). Its income comes from dividends, a little interest, and realised or fair-value gains on securities, so earnings swing with Indian equity markets. The company has no borrowings, pays no dividends, has a very small cost base, and trades at about 0.27 times book value. In September 2025 governance passed to the next promoter generation, when Mrs. Aarisha became Managing Director. Returns on equity are below 1% and there is no stated growth strategy. The stock is best understood as an illiquid, discounted proxy for a closely held equity portfolio. --- **Company's own description.** The company's filings and data-vendor summaries of them describe the business in four consistent ways: - It operates in loan financing, trading in shares, and miscellaneous financial services. - Its income comes from investments in shares and securities, interest on loans it has financed, and miscellaneous financial activities (Business Standard, JM Financial, mStock). - Screener's summary of the FY2024 Annual Report notes that the company currently focuses mainly on share trading. - The Directors' Reports for FY2025 (31st Annual Report) and FY2026 (32nd Annual Report) follow standard NBFC reporting formats, including a transfer to the statutory reserve fund. Tickertape's description adds that the company deals in financial markets, leasing, hire purchase and related activities. This reflects the objects clause in its memorandum rather than current activity. **Independent characterisation.** On the evidence of the FY2025 and FY2026 accounts, Arihant's Securities is an equity investment holding vehicle that happens to be licensed as an NBFC. It is not an operating lender in any meaningful sense: Source: ScanX summary of the FY2026 audited results and annual report (published 18-Aug-2026). **Business model and revenue model.** The company earns money in three ways: 1. **Dividend yield** on a portfolio of listed equities. This is recurring but small at about 0.5% of the investment book. 2. **Trading and realised gains** on securities. These are lumpy and pro-cyclical. 3. **Interest** on occasional loans or advances. This is minimal. There is no product, subscription or licensing revenue. The P&L has no fee or brokerage line, although ScanX's commentary refers to "core brokerage" generically. The company is not a SEBI-registered stockbroker on the evidence reviewed. **Value-chain position.** The company is an end investor, a capital allocator using its own balance sheet. It sits at the buy-side end of the capital-markets value chain and has no client-facing intermediation. **Customers and end-markets.** The company has no external customer base in the usual sense. Its "end-market" is the Indian listed equity market, mainly BSE- and NSE-listed stocks. Historically it may have had small borrowers in its loan-financing activity. Their identity, number and size are not publicly disclosed. **Cost structure.** Total expenses were about ₹0.60 crore in FY2026, made up of employee costs, listing and compliance fees, audit fees, RTA and depository charges, and other administrative costs. Depreciation and finance costs are zero. Executive directors drew no remuneration in FY2026 (ScanX FY26 summary).

RevenueN/A
EmployeesN/A
Market Cap$0.0B
Founded1994
Chennai, India

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Arihant

Arihant Capital Markets Limited

Premium
Information Technology

Arihant Capital Markets is a family-promoted, Indore-headquartered, full-service retail broking and financial-services group with more than three decades of operating history. The company describes itself as central India's largest stock-broking firm. Its franchise is built around a hybrid distribution model: an extensive network of franchise "investment centres" and own branches across Tier-2 and Tier-3 India, overlaid since the 2020s with a digital trading stack under the Arihant Plus brand. Revenue is dominated by brokerage across equity, derivatives, commodity and currency. It is complemented by interest income from margin funding, client float and the NBFC subsidiary, plus merchant banking, distribution of mutual funds and other products, PMS, depository and research. The group is mid-way through a composite restructuring. That scheme would collapse its NBFC subsidiary into the listed parent and then demerge a lending, merchant-banking and distribution vertical into a second listed company, Arihant Elite Financial Solutions. The aim is to separate broking from lending. Earnings are highly cyclical and tied to market turnover. --- **Company's own description.** In its corporate presentations, Arihant describes itself as a leading Indian financial-services company and central India's largest stockbroker. It lists equity broking, commodity and currency broking, wealth management, merchant banking, insurance, mutual funds and PMS among its services. Its stated mission is to make every Indian financially independent through investment products, service and "client first" guidance (Company Profile deck; Investor Presentation, May 2024). Exchange-registered descriptions note that the company is registered with SEBI under the stock brokers regulations and is a member of BSE, NSE, MCX and NCDEX. The Directors' Report for FY2025 (33rd Annual Report) states the FY2026 aims: broaden capabilities across the value chain, introduce new products and services, and widen revenue streams. **Independent characterisation.** ACML is a mid-tier, transaction-driven intermediary. Its earnings are leveraged to Indian retail market activity, particularly F&O and cash-equity volumes. Its business model has four economic engines: 1. **Brokerage (agency) income.** These are commissions on client trades across segments. They are the largest single line, at about INR 124 Cr in FY2026 and INR 139 Cr in FY2025 (StockAnalysis, from filings). The company shares a meaningful portion with franchise partners. This shows up as "fees and commission expense", for example INR 24.12 Cr in Q1 FY2027 against INR 14.77 Cr in Q1 FY2026 (Q1 FY2027 results). 2. **Interest and float income.** This covers margin trading funding (MTF), interest on client funds and fixed deposits placed with exchanges, and NBFC lending through Arihant Financial Services Ltd (AFSL). Interest and dividend income was about INR 80 Cr in FY2026, against interest expense of about INR 22 Cr. 3. **Fee-based advisory.** This comprises merchant and investment banking (SEBI Category-I activity through the group), PMS, depository-participant fees and research. 4. **Distribution.** This includes mutual funds, NPS, gold, bonds and, until FY2026, insurance broking, which was exited through the sale of Arihant Insurance Broking Services Ltd. **Revenue model mix.** The business is essentially all service and transaction revenue. It has no product sales, no licensing and only minimal subscription income. Brokerage is about 60%, interest and dividend income about 35 to 40%, and fee and other income makes up the rest. The split is based on FY2026 line items as reported by StockAnalysis; the company does not publish this split as a segment. **Value-chain position.** ACML is a SEBI-registered trading and clearing member and a depository participant (CDSL/NSDL). It sits between retail and HNI investors and the exchange and clearing infrastructure. It also originates small-cap capital-markets transactions (merchant banking) and distributes third-party manufacturers' products. **Customer types.** These are retail individuals (the core), HNIs (through the "Arihant Platinum" proposition), corporates (merchant banking, ESOP/treasury services), and institutions and mutual funds (institutional broking and research). The Yahoo Finance/S&P profile lists HNIs, mutual funds and financial institutions, and corporates as served segments. **End-markets.** These are Indian equity cash and derivatives, commodity derivatives (MCX/NCDEX), currency derivatives, primary markets (IPOs, SME issues), mutual-fund distribution, and secured lending against securities. Geographic concentration is in Madhya Pradesh and central and western India. There is a GIFT City presence through Arihant Capital (IFSC) Ltd.

Revenue$0.0B
Employees314
Market CapN/A
Founded1992
United States, North America
AriesAgro

Aries Agro Limited

Premium
Information Technology

Aries Agro is one of India's longest-established specialty plant-nutrition companies and a pioneer of chelated micronutrient fertilisers in the country, having introduced the Agromin chelated micronutrient mixture in 1975 and Chelamin chelated zinc in 1976. It is a promoter-controlled micro-cap (Mirchandani family 52.66%) whose business is almost entirely domestic, dealer-distributed, highly seasonal, and working-capital intensive. Its product basket spans chelated and non-chelated micronutrients, secondary nutrients (sulphur, calcium, magnesium), water-soluble and specialty fertilisers, bio-stimulant-type plant-health products, and a small but fast-growing farm-equipment/pest-trap line. CRISIL (January 2022) estimated the group's share of the organised domestic chelated-micronutrient market at roughly 30%, making it the category leader. After a decade of stagnant returns, FY2025–FY2026 marked an inflection: consolidated revenue grew ~19–20% per year, PAT more than doubled over two years, net debt fell to near zero, and the working-capital cycle compressed sharply — catalysing a re-rating of the stock. --- ### What the company does Aries Agro manufactures, imports, formulates and markets micronutrients and other customised nutritional products, principally for plants and historically also for animals (the company's origin was mineral feed additives for livestock and poultry). Today, the plant-nutrition business dominates: the company reports a single operating segment labelled "Micronutrient Fertilizers" in its exchange filings (iXBRL, Q2 FY2026). The product range covers: **Micronutrients:** zinc, iron, manganese, copper, boron, molybdenum, in chelated (EDTA-type metal chelates) and non-chelated forms, both single-element and multi-nutrient mixtures (flagships Agromin and Chelamin). **Secondary nutrients:** sulphur, magnesium and calcium (added 2001), including sulphur bentonite and sulphur-based pastillated products manufactured in the UAE. **Specialty and water-soluble nutrition:** crop-specific formulations (e.g., Majorsol Soybean & Pulses Special), concentrated liquid micronutrients (Zinc HD Gold, Agromin Max HD), calcium–magnesium sources (Calmax), silicon (Aries Silica). **Plant-health / immunity / bio-inputs:** Aries Ecoshield (plant immunity booster), bio-fertilisers (entered with the Ahmedabad unit in 2008). **Agri-equipment and IPM devices:** via subsidiary Aries Agro Equipments Pvt Ltd (e.g., Magic Traps, Aries Trap X, Aries Suraksha) and soil-management technology (Aries Soil Wrap). The company also maintains exclusive marketing arrangements with overseas plant-nutrition manufacturers (Europe, Turkey, Singapore, USA, South America), adapting imported products to Indian conditions — a "Made for India" positioning it has long used (company profile). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely product sales (manufactured and traded fertiliser products). No meaningful service, subscription or licensing revenue disclosed. | | Channel | Business-to-business-to-farmer: sales to dealers/distributors who extend credit to retailers and farmers. FY2026 annual booking involved 1,717 dealers across 26 states (Board's Report FY2025). | | Demand-booking mechanism | An annual "booking bazaar" / online booking app where dealers place forward bookings for the year: INR 835.10 cr booked for FY2025 and INR 830.44 cr for FY2026 (MD&A FY2025; Board's Report FY2025). | | Gross-to-net | Significant trade discounts/rebates: consolidated FY2025 gross revenue INR 804.59 cr vs. net revenue INR 622.22 cr (discounts ~INR 182 cr, ~22.6% of gross). FY2026 gross INR 956.88 cr vs. net INR 740.06 cr. | | Seasonality | Strong concentration in Q2 (kharif) and Q3 (rabi); Q4 is structurally weak and frequently loss-making (Q4 FY2026 consolidated loss of INR 4.79 cr). Management explicitly flags cropping patterns, seasonality and weather as drivers (Q1 FY2027 press release). | | Value-chain position | Mid-stream formulator/manufacturer: imports or buys metal salts, chelating agents, sulphur, etc.; formulates, packages and brands; relies heavily on field-extension marketing (3,958 farmer meetings reaching 54,948 farmers in FY2026). | | Customers | Dealers/distributors (direct customers); end users are farmers — field crops (cereals, pulses, oilseeds, sugarcane) and high-value horticulture (grapes, potatoes, mangoes, vegetables). Institutional/government sales: not separately disclosed. | | End-markets | Indian agriculture overwhelmingly; limited exports/overseas sales via the UAE subsidiary (Golden Harvest Middle East FZC) and associate (Amarak Chemicals FZC). | ### Company's own description vs. independent characterisation **Company's description (paraphrased from FY2026 press release and FY2025 Annual Report):** Aries describes itself as one of India's leading plant-nutrition and specialty agri-input companies with a 57-year legacy, deep farmer connections, a diversified product portfolio and an innovation-led approach, aiming to become a globally competitive agri-nutrition enterprise. **Independent characterisation:** Aries is a niche, promoter-run, India-centric specialty fertiliser formulator that is unsubsidised (micronutrients sit outside India's Nutrient Based Subsidy regime for primary fertilisers), brand- and extension-driven, and historically constrained by a very long cash-conversion cycle and thin net margins (3–4%). The FY2025–FY2026 improvement appears driven by operating leverage, lower interest costs from deleveraging, and much tighter receivables management rather than by a structural change in the business model. It remains small (FY2026 net revenue ~INR 740 cr, ~USD 85–90 m) relative to diversified fertiliser majors that also sell micronutrients.

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1969
Mumbai, India
Archies

Archies Limited

Premium
Information Technology

Archies Limited is India's best-known legacy brand in the "social expression" category: greeting cards, gifts, soft toys and stationery sold under the Archies name. It has been active for more than four decades. The company manufactures at Manesar, Haryana and sells through company-owned stores, franchisees, distributors, third-party retailers and, increasingly, quick-commerce platforms such as Blinkit. Once a INR 100+ crore revenue business (total revenue of INR 119.38 crore in FY2008), Archies has shrunk structurally as greetings moved to digital media. Revenue from operations fell to INR 56.1 crore in FY2026, and the company has reported losses in four of the last five fiscal years. Revenue is heavily concentrated in North India (about 82% in H1 FY2026), and the owned-store network has contracted to 54 stores (September 2025). Management's turnaround thesis rests on three levers: a compact "Archies Express" store format aimed at Gen Z, quick-commerce channels, and a revival of exports. Execution so far has not arrested the revenue decline. --- **Company's own description.** In its 2 March 2026 press release filed with the exchanges, the company describes itself as a "legacy brand in the social expression industry" that has operated a chain of greeting-card and gift stores for about 45 years. It says it sells through company-owned stores, retailers, franchisees and distributors. The FY2025 Directors' Report (35th Annual Report) states that company-owned and managed stores contributed significantly to revenue from operations and to profits. **Independent characterization.** Archies is a vertically integrated, brand-led specialty retailer and wholesaler of low-ticket emotional-gifting products. It has three main business characteristics. **In-house manufacturing:** The company designs and produces greeting cards and paper stationery, and some gift items, at its Manesar plant. ICRA identifies PVC, polypropylene and plywood as key raw materials for the gifting and stationery manufacturing it undertakes. **Bought-in merchandise:** It sources finished goods such as soft toys, chocolates, fragrances, lifestyle accessories and seasonal merchandise. Quarterly filings show "purchase of traded goods" as a material cost line, for example INR 4.44 crore in Q4 FY2025 and INR 3.15 crore in Q3 FY2026 (aggregator reproduction of filed results). **Multi-channel distribution:** Channels are the owned store network (54 stores as of September 2025, down from a much larger historical network), franchise outlets, distributors and general trade, B2B/institutional orders, quick commerce (Blinkit), and episodic export orders. **Revenue model.** Revenue is almost entirely from product sales; there is no meaningful service, subscription or licensing income. The company has not disclosed the split between retail and wholesale or franchise revenue. Other income, including rental and miscellaneous income and gains on asset disposals, has been material relative to operating profit. For example, other income was INR 4.24 crore in Q1 FY2026 against an operating loss before other income of INR 3.00 crore in the same quarter. This means reported net results flatter the core business. **Value-chain position.** Archies spans design, manufacture, branding and distribution, and retail. That integration preserves gross margin but brings high fixed costs (plant, store leases and staff) and high inventory intensity. ICRA reports working-capital intensity of 104.7% of operating income in FY2026. **Customers and end-markets.** Customers are mass and middle-market Indian consumers buying for festivals and occasions: Valentine's Day, Diwali, Raksha Bandhan, Friendship Day, birthdays, New Year, and Mother's and Father's Day. The core demographic is urban youth and young families. The new Express format explicitly targets millennials and Gen Z. Secondary customers are retailers, franchisees and distributors; quick-commerce platforms; corporate and B2B buyers (for example, a 2024 purchase order from Daks India Industries); and overseas buyers (export orders, including a US order cancelled in FY2026 because of US tariff changes). **Seasonality.** The business is strongly seasonal. Q2 (July–September: Friendship Day, Raksha Bandhan) and Q3 (October–December: Diwali, New Year) are typically the strongest quarters. Q4 benefits from Valentine's Day. Q1 is structurally the weakest.

Revenue$0.0B
Employees487
Market CapN/A
Founded1979
United States, North America
Arcee

Arcee Industries Limited

Premium
Information Technology

Arcee Industries Limited is a Hisar, Haryana–based micro-cap industrial company historically engaged in manufacturing rigid PVC pipes and fittings and, between January 2021 and May 2023, black (mild) steel tubes and pipes from a leased related-party plant. The company enjoyed a brief revival in FY2021–FY2023, when steel-pipe trading volumes lifted revenue to a peak of ₹34.25 Cr in FY2022, but cancellation of the steel-unit lease in May 2023 and an inability to fund PVC-pipe working capital led to a complete halt in production from August 2023. Revenue has since collapsed to ₹0.10 Cr (FY2026) and the company has posted losses in each of the last four fiscal years. In 2026 the company embarked on a capital restructuring: new whole-time directors, a tripling of authorised capital, a change of statutory auditor, and the allotment of 2.13 Cr convertible warrants to 29 non-promoter investors (₹22.04 Cr aggregate), which upon conversion would dilute the existing promoter group to under 5%. It is best characterised today as a dormant listed shell in transition, not an operating pipe manufacturer. --- ### What the company does (company's own characterisation) The company describes its principal activity as the production of rigid PVC pipes and steel pipes. In its financial-results notes it states that its entire operation relates to two segments — PVC pipe and steel pipe ("Rigid PVC Pipes & M.S. Tubes"). Its FY2025 annual report explains that the company had taken on lease the land, building and machinery of Arcee Ispat Udyog Private Limited — a black steel tubes and pipes manufacturing unit — for ten years in FY2020, commenced commercial steel-pipe production on 14 January 2021, and, owing to continuing losses in steel-pipe manufacturing, cancelled that lease on 22 May 2023. The company's quarterly result notes from December 2023 onward add that it has been seeking finance for working capital to restart PVC pipe production but has not been able to arrange it. ### Independent characterisation On the evidence of filings, Arcee Industries is presently a non-operating listed entity. Key observations: **Operations halted:** Third-party summaries of the company's filings report that production at the manufacturing unit ceased in August 2023 due to finance/working-capital constraints, and the FY2026 results commentary (Pocketful summary) indicates the company has ceased production and is selling assets to settle dues. **Residual revenue:** FY2026 revenue from operations was ₹0.10 Cr (≈₹9.90 lakh), down ~35% year-on-year, likely reflecting liquidation of residual inventory rather than manufacturing output (inference; the precise nature of FY2026 sales is not publicly disclosed in sources reviewed). **Asset run-down:** Net fixed assets fell from ₹1.96 Cr (FY2023) to ₹0.88 Cr (FY2026); cash inflow from investing activities of ₹0.27 Cr (FY2025) and ₹0.33 Cr (FY2026) is consistent with disposal of plant and equipment. **Recapitalisation underway:** The ₹22.04 Cr warrant issue (25% received, ≈₹5.51 Cr) is the only material source of new capital. The stated objects in the January 2026 proposal were working capital and brand visibility; no specific restart plan, product launch, or business pivot has been publicly detailed in sources reviewed. ### Business model and revenue model | Dimension | Historical model (FY2021–FY2023) | Current status (FY2024–FY2027 YTD) | |---|---|---| | Revenue type | 100% product sales (manufactured goods); no service, subscription or licensing revenue | Negligible residual product sales | | Product mix | Rigid PVC pipes & fittings (own plant, Hisar); black steel tubes & pipes (leased plant of related party Arcee Ispat Udyog) | No production since August 2023 | | Value-chain position | Mid-stream converter: buys PVC resin/compounds and steel coils/strips (HR coil), converts into pipes | Not operating | | Customer types | Not publicly disclosed in detail; rigid PVC pipes in this region typically sell via dealers/distributors to agriculture (irrigation), plumbing and building contractors; steel pipes to fabricators, traders and structural users (industry characterisation, not company-specific disclosure) | — | | End-markets | Agriculture/irrigation, construction & plumbing, general engineering (industry characterisation) | — | | Pricing model | Commodity spread (realisation minus resin/steel input cost); not publicly disclosed | — | ### Revenue mix | Revenue type (₹ Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Product sales (total revenue from operations) | 34.25 | 21.36 | 1.07 | 0.15 | 0.10 | | Services / subscription / licensing | 0 | 0 | 0 | 0 | 0 | Source: Screener.in (C-MOTS data compiled from BSE filings), standalone, FY2022–FY2026.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1989
Hisar, India
ARCFinance

ARC Finance Limited

Premium
Information Technology

ARC Finance Limited is a 44-year-old Kolkata company that began life as ARC Modellors & Services, became a finance company in 1993 and has held an RBI licence as a non-deposit-taking NBFC since 1998. It lends money (secured and unsecured, to individuals and corporates), invests and trades in securities, and says it has diversified into third-party financial-product distribution. With a balance sheet of about INR 114 Cr, net worth of about INR 99 Cr and a loan book of about INR 87 Cr at March 2026, it sits in the Base Layer of RBI's scale-based framework, among several thousand small NBFCs. Its distinctive features are capital-markets rather than operational: a 4-for-5 rights issue in late 2024 that nearly doubled the share count and equity; promoter ownership of only 6.97%; and a shareholder base that grew from about 1,100 in 2021 to over 3 lakh. Profitability is thin and erratic, with a three-year average ROE below 2%. --- **Company's own description.** In its annual-report material (as summarised by Screener from the FY2025 annual report), the company describes itself as a non-systemically-important, non-deposit-taking NBFC. It says it advances loans, invests in and trades securities, and has diversified into businesses ranging from third-party product distribution (described as the lowest balance-sheet risk) to originating unsecured personal loans and corporate loans (described as the highest balance-sheet risk). It also says it offers a range of other financial services to customers. Older corporate summaries add that around 2015 the company, which had manufacturing and trading activities in agricultural and other products, took up financial and investment activities. **Independent characterisation.** The financial statements describe a business with three income engines whose relative weight cannot be fully separated from public data: 1. **Interest income on loans.** The loan book is the clearest operating asset. It appears on the balance sheet only from FY2024 (INR 44.57 Cr), rising to INR 69.96 Cr at FY2025 and INR 86.90 Cr at FY2026 (Finology; Whalesbook summary of FY2026 results). Loans were 76% of total assets at March 2026 (derived). The growth was funded mainly by the INR 44 Cr rights issue rather than borrowing. 2. **Securities investment and trading.** The company holds stock-in-trade and investments. Reported revenue swings sharply from quarter to quarter: Q2 FY2026 total revenue of INR 20.05 Cr against INR 0.82 Cr in Q1 and INR 1.58 Cr in Q3 (HDFC Sky). That pattern fits lumpy sales of securities booked as revenue, not steady interest accrual. 3. **Distribution and fee income.** The company mentions third-party product distribution, but the materials reviewed do not quantify it. **Revenue model mix.** Capital Market (via Business Standard) reports FY2026 "Sales" of INR 6.14 Cr, while revenue from operations was INR 28.09 Cr. The difference of about INR 22 Cr most plausibly reflects proceeds from sale of securities/stock-in-trade, which aggregators handle inconsistently. This is the analyst's inference and has not been confirmed against the notes to accounts. On that reading, the more recurring interest/fee component was about INR 6 Cr in FY2026, roughly 7% of the average loan book (derived). That is a plausible yield for a small NBFC lending to related or semi-related corporate borrowers and individuals. **Value-chain position.** ARC is a balance-sheet lender funded almost entirely by equity (debt/equity 0.01 at FY2025, Value Research). It has no disclosed branch network, digital platform, co-lending arrangements or bank funding lines. It is a capital provider, not an originator-distributor. **Customer types and end-markets.** The filings name only broad categories: individuals (unsecured personal loans) and corporates (corporate loans). Borrower concentration, geography, ticket sizes and sector exposures are not publicly disclosed. Given the Kolkata registered office and the absence of a branch network, the lending is likely concentrated in eastern India and in a small number of counterparties. This is the analyst's inference.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1982
Kolkata, India
Aravali

Aravali Securities & Finance Limited

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Aravali Securities & Finance Limited | BSE filings; Screener.in | | Former names | Aravali Trader And Investments Company Limited (at incorporation, 1980); Aravali Leasing Limited (date of change not publicly disclosed); renamed Aravali Securities & Finance Limited on 4 May 1994 | ICICIdirect / Business Standard company background (sourced from Capitaline/Capital Market) | | Founding / incorporation | 11 June 1980, New Delhi, as a public limited company | Nirmal Bang stock summary; ICICIdirect | | Incorporation jurisdiction | India (Companies Act). Currently registered with the Registrar of Companies, Delhi & Haryana | CS resignation filing, Nov 2025 | | Corporate Identity Number (CIN) | L67120HR1980PLC039125 | Board meeting intimation to BSE, 1 May 2026 | | Registered office / HQ | Plot No. 136, Ground Floor, Rider House, Sector-44, Gurugram (Gurgaon), Haryana 122003, India. Some vendor databases (mStock) list the 4th floor of the same building. Moved from New Delhi to Gurgaon in 2009 | Board meeting intimation, May 2026; Kotak Securities company background | | Telephone | +91-124-4284578 / 4284580 / 4284582 | Board meeting intimation, May 2026 | | Stock exchange and ticker | BSE Limited, scrip code 512344, symbol ARAVALIS. Not traded on NSE (see discrepancy note below) | Screener.in; Tickertape; Nirmal Bang | | ISIN | INE068C01015 | Nirmal Bang; FinancialFilings | | CUSIP | Not applicable (no US listing) | — | | Face value | INR 10 per share | Screener.in | | Shares outstanding | 1,51,53,800 equity shares (equity capital INR 1,515.38 lakh ÷ INR 10) | FY2026 audited balance sheet | | Fiscal year end | 31 March | Company results | | Registrar & transfer agent | Skyline Financial Services Pvt Ltd, D-153/A, 1st Floor, Okhla Industrial Area Phase-I, New Delhi 110020 | mStock; Reg 74(5) certificates | | Statutory auditor | M/s Rajan Goel & Associates, Chartered Accountants (Firm Registration No. 004624N). Unmodified opinion on FY2026 results; unmodified limited review on Q1 FY2027 | FY2026 results outcome, 8 May 2026; Q1 FY2027 results, 12 Aug 2026 | | Employees (latest) | Headcount not publicly disclosed in sources reviewed. Employee benefits expense was INR 48.12 lakh in FY2026 and INR 49.34 lakh in FY2025, which implies a very small team | FY2026 audited results | | Employees (3-year trend) | Headcount not publicly disclosed. Employee cost proxy: INR 0.46 cr (FY2024), INR 0.49 cr (FY2025), INR 0.48 cr (FY2026) | Tickertape income statement | | Market capitalisation (current) | About INR 5.75–5.86 crore at the 19 Oct 2026 close of INR 3.80 | Screener.in (INR 5.75 cr); Tickertape (INR 5.86 cr); ScanX (INR 5.79 cr) | | 52-week range | INR 3.35 – 6.54 | Screener.in; Tickertape | | Website | www.aravalisecurities.com | Screener.in; Simply Wall St | | Promoter group | Poddar family; 54.56% promoter holding as of Sep 2026 | Kotak Securities background; Screener.in shareholding | | Surveillance status | Trendlyne showed a GSM (Graded Surveillance Measure) tag on the BSE quote page as of July 2026 | Trendlyne quote page, 10 Jul 2026 | The entity named in the request is the one profiled here. There has been no name change since 1994 and no change of listing venue. The BSE scrip code is 512344 and the BSE symbol is ARAVALIS, which matches the Yahoo-style ticker ARAVALIS.BO given in the request. Aravali Securities & Finance Limited is a Gurugram-based, Poddar-family-promoted listed shell of a former leasing and investment company. It began in 1980 as a trading-and-investment vehicle and later operated as a leasing and hire-purchase financier and paper distributor. Its active financing book has largely run off. Today it reports nil revenue from operations. Almost all of its roughly INR 95 lakh annual income is lease/rent income from enterprises in which its directors or their relatives have significant influence. The company describes itself as providing financial and other advisory services and dealing in shares and securities, and says it is looking for new business avenues. Its capital position is the key fact for any investor. Accumulated losses have eroded the entire INR 15.15 crore of paid-up capital, leaving net worth of minus INR 1.10 crore at FY2026. The company depends on director and affiliate funding, and its governance record includes recent BSE penalties. It is best understood as a balance-sheet and governance-restructuring situation, not an operating financial-services franchise. --- ### Company's own description In its recent annual report, the company says it is engaged in providing financial and other advisory services besides dealing in shares and securities. It adds that it is constantly looking for new business avenues that can be taken up alongside the existing business (Annual Report FY2026, Business Overview, as summarised by Screener.in). In its FY2026 results filing, the company states that it operates in a single segment, financial and other advisory services, with no separate reportable operating segments under Ind AS 108 (FY2026 audited results, 8 May 2026). Older descriptions from data vendors, derived from historical annual reports, portray a different company. It was a non-banking financial company (NBFC) engaged in leasing, bill discounting, hire-purchase, and trading and investment in shares and securities. Its lease book covered earthmoving equipment, general machinery, vehicles and computers. It also acted as a Delhi and Calcutta distributor of paper manufactured by Orient Paper Mills and The Sirpur Paper Mills (Kotak Securities company background, sourced from Capital Market). ### Independent characterisation The reported financials show a company whose economic substance has narrowed to three things: 1. **Lessor of property/assets to related enterprises.** In FY2026, lease/rent income from related enterprises was INR 92.72 lakh, against total income of INR 95.47 lakh. That is about 97% of total income. The named related enterprises are Carma Arts & Crafts Private Limited, Devi Overseas Private Limited and Remus India Private Limited (Reg 23(9) RPT disclosure, 8 May 2026). The likely leased asset is the company's fixed-asset base: net block of INR 1.83 crore at FY2026 and non-current assets of INR 280.63 lakh. The specific asset and lessee mapping is not publicly disclosed in the sources reviewed. 2. **A residual investment holding.** Investments were only INR 0.09 crore at Mar 2026, down from INR 28.24 crore at Mar 2015. Screener's AI extraction refers to a holding in an HDFC liquidity/liquid mutual fund, with values not publicly visible. 3. **A borrower from insiders.** Borrowings were INR 369.41 lakh, all current. Year-end payables were INR 272.06 lakh to directors and INR 160.80 lakh to related enterprises. Interest expenditure to directors (INR 54.07 lakh) and related enterprises (INR 10.80 lakh) is disclosed in the RPT statement. The company has no operating revenue and only a small cost base: about INR 1.14 crore of expenses including finance cost in FY2026. It is therefore functionally a holding/lessor shell. Its listed status and a long-established shareholder register (17,277 shareholders, Sep 2026) are arguably its most distinctive assets. ### Business and revenue model mix | Revenue component | FY2026 (INR lakh) | Share of total income | Nature | Source | |---|---|---|---|---| | Revenue from operations | 0.00 | 0% | Nil reported | FY2026 audited results | | Other income: lease/rent from related enterprises | 92.72 | ~97.1% | Recurring rental, related-party | Reg 23(9) RPT disclosure | | Other income: balance (interest, fair-value or other items) | 2.75 | ~2.9% | Residual; breakdown not publicly disclosed | Derived: 95.47 − 92.72 | | Total income | 95.47 | 100% | — | FY2026 audited results | The product, service, subscription and licensing mix is not applicable. The company sells no products, runs no subscriptions and has no licensing income. Within the financial-services value chain, it is at most a capital-market participant and a lender/borrower at micro scale. In practice it sits outside any active value chain. **Customer types:** Effectively three private companies related to the promoter group (the lessees). No third-party customer base is disclosed. **End-markets:** India only. The rental income is earned from domestic private companies. Any securities activity would be in Indian capital markets. **Data-classification note:** Screener.in shows small "Sales" figures for FY2023–FY2026 (INR 0.05, 0.02, 0.02, 0.03 crore), while the company reports nil revenue from operations for FY2025 and FY2026. This appears to be a vendor reclassification of a minor income line. The company's own presentation is used where they conflict.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1980
Gurugram, India
Aprogen

Aprogen pharmaceuticals,Inc.

Premium
Information Technology

Aprogen Biologics is a loss-making, majority-controlled Korean pharmaceutical and biologics manufacturer. It combines a 65-year-old domestic ethical-drug business, inherited from Kunpoong and Schnell, with one of Korea's largest perfusion-based antibody plants in Osong. Group materials put the plant's investment at about KRW 600 bn and its capacity at roughly 3,000 kg of antibody a year. Within the Aprogen group, the company is the designated manufacturer for biosimilars and novel biologics developed by its parent, Aprogen Inc. These include the infliximab biosimilar GS071, the trastuzumab biosimilar AP063, and the adalimumab and rituximab candidates AP096 and AP056. In Q1 2026, however, Osong recorded zero litres of biologic output, and the company has posted operating losses of KRW 52.8–60.4 bn a year since FY2023. A newly reported semiconductor segment is currently its only profitable division. The investment case rests on AP063 approvals following FDA and EMA regulatory feedback that waives Phase 3, on the first commercial CDMO contracts, and on how long the parent can continue funding the company. --- ### What the company does Aprogen Biologics operates three reportable activities, plus residual "other" items. 1. **Pharmaceutical business (제약사업부문).** This is the legacy Kunpoong/Schnell business: manufacture and domestic sale of prescription and generic medicines. Third-party profiles describe the line-up as including amino-acid infusion products and antibiotics (Dealroom). Asia Economy (June 2020) described the predecessor, Aprogen Pharmaceuticals, as an antibiotics-focused drug maker. Recruitment postings (Catch, 2026) refer to a Hwaseong plant with a tablet-coating production line, a regulatory-affairs (RA) development team, and a "CSO support team." The CSO reference indicates the company uses contract sales organisations for domestic marketing. In Q2 2026 the segment generated 62% of revenue (Butler). 2. **Bio business (바이오사업부문).** This is the Osong cGMP biologics plant acquired through the December 2022 merger with the former unlisted Aprogen Biologics. The plant was completed in January 2020. It holds the following capacity: - **Drug substance:** four 2,500 L bioreactors (2,000 L working volume) and two 250 L bioreactors, designed for perfusion culture. - **Drug product:** fill-finish lines for lyophilised vials, liquid vials, prefilled syringes and auto-injectors. The segment's intended revenue streams are (a) manufacturing the Aprogen group's biosimilars and (b) third-party CMO/CDMO work. In Q2 2026 the segment contributed only 3% of revenue (Butler) and generated nearly all of the operating loss: about KRW 13.2 bn in Q1 2026 and about KRW 30.5 bn in H1 2026 (IB Tomato). 3. **Semiconductor business (반도체사업부문).** This segment appears in 2026 segment reporting. It contributed 33% of Q2 2026 revenue and an operating profit of about KRW 2.25 bn in H1 2026 (Butler; IB Tomato). Its origin, legal form and products could not be confirmed in sources reviewed. Elsewhere in the group, semiconductor-equipment parts are made by N2Tech (엔투텍, vacuum gate valves), which group-level profiles associate with Aprogen Inc. (Valueline). ### Business and revenue model | Revenue stream | Type | Status (2026) | |---|---|---| | Domestic prescription / generic drugs | Product sales | Core revenue; segment profitable in Q1 2026 (KRW 1.8 bn operating profit), loss-making in H1 2026 (about –KRW 3.3 bn) | | Biosimilar manufacturing for the Aprogen group | Contract manufacturing / intra-group supply | No commercial output in Q1 2026 (0 L produced) | | Third-party CMO/CDMO | Service | Trial fill-finish run for a "Company C" completed (Hankyung, January 2025); audits by a European "Company O"; no commercial contract confirmed in sources reviewed | | Semiconductor products | Product sales | 33% of Q2 2026 revenue; only profitable segment in H1 2026 | | Related-party services | Service | Aprogen Inc. recorded about KRW 1.9 bn of service transactions with the company between March and August 2026 (IB Tomato) | Licensing income does not appear to be booked at Aprogen Biologics. Biosimilar IP and out-licensing rights sit with Aprogen Inc. Partner Nichi-Iko paid upfront fees of KRW 10 bn each for GS071, AP063 and AP056 to Aprogen, not to the listed predecessor (Medical Times, March 2016). Under the 2020 group restructuring plan, the listed predecessor held domestic biosimilar sales rights. Asia Economy also reported that a profit-allocation agreement on production from the Osong facility was planned. Its current terms are not publicly disclosed. ### Value-chain position, customers and end-markets **Value-chain position:** Downstream manufacturer within a vertically split group. In the 2020 design, Aprogen Inc. does R&D, the listed predecessor does sales, and Aprogen Biologics does production. After the December 2022 merger, the listed entity carries both the sales (pharma) and production (bio) roles. **Customers:** - Pharma: hospitals, clinics and pharmacies in Korea, served directly and through CSOs and distributors. - Bio: Aprogen Inc. (captive) and prospective third-party biopharma CDMO clients in Korea, Japan and Europe. - Semiconductor: not disclosed. **End-markets:** Korean prescription-drug market; global biosimilar supply (indirectly, through Aprogen's partners such as Nichi-Iko in Japan); global biologics CDMO; semiconductor supply chain (details undisclosed). ### Company self-description vs. independent characterisation The company's English-language self-description in its latest annual report was not accessible in sources reviewed. Group investor materials (Aprogen IR, June 2025) present Osong as a facility with globally unmatched manufacturing cost. They state that a single 2,500 L perfusion bioreactor batch (about 200 kg before purification for AP096) equals the output of four to six 15,000 L fed-batch bioreactors at competitors. The group targets a "Global Top Tier CDMO" position and expected a turnaround around 2027. **Independent characterisation.** Aprogen Biologics is a sub-scale domestic generic-drug company carrying a large, idle biologics asset. Its losses are structural. Fixed costs at Osong, including about KRW 3.1 bn of quarterly depreciation on KRW 152.8 bn of machinery (Q1 2026), are not covered by output, and the plant's utilisation depends on regulatory milestones of the parent's biosimilars. Since 2024 the company has relied on related-party funding: placements to the parent, convertible bonds bought by affiliates, and parent loans. It has also pledged its own core real estate as collateral for the parent's borrowings. The semiconductor segment adds diversification but has no stated strategic link to the biologics business.

Revenue$0.1B
Employees262
Market CapN/A
Founded1960
United States, North America
Apollo

Apollo Finvest (India) Limited

Premium
Information Technology

Apollo Finvest is a 41-year-old Mumbai-based, family-promoted, BSE-listed NBFC that has re-invented itself since roughly 2018–19 as a technology-first lending infrastructure company. Under MD & CEO Mikhil Innani (co-founder of PharmEasy, ex-product head at Hotstar) and Whole-Time Director & CFO Diksha Nangia (ex-HDFC, CFA charterholder), it marketed itself as the "AWS of digital lending": a regulated balance sheet plus in-house loan-management software (Sonic) and APIs that let fintechs launch credit products quickly. RBI's 2022 Digital Lending Guidelines and the 2023 5% cap on first-loss default guarantees broke its original lending-service-provider model, forcing a pivot toward term loans to digital NBFCs, co-lending and, from October 2025, a direct-to-consumer app, Apollo Cash. It is small (FY26 revenue ₹20.7 Cr, net profit ₹6.95 Cr), debt-light, consistently profitable, non-dividend-paying and roughly 71% promoter-owned. Its investment case now rests on whether Apollo Cash can scale with sound credit quality. --- ### What the company does Apollo Finvest is an RBI-regulated lender that originates and holds small-ticket, digitally sourced credit. Its business has passed through three identifiable models: 1. **Lending-as-a-service / LSP model (c. FY2019–FY2023).** Fintech "lending service providers" (LSPs) sourced, underwrote and often collected loans that were booked on Apollo's balance sheet using Apollo's NBFC licence and technology. Fintechs typically provided first-loss default guarantees. Apollo collected interest and passed a large portion to partners as commissions/service costs. Company material from 2023 claims work with 50+ fintechs and disbursement of over 17 lakh loans. 2. **Partnership-capital model (FY2024–FY2026).** After the RBI Digital Lending Guidelines (DLG) and the June 2023 FLDG framework capping guarantees at 5% of the portfolio, Apollo pruned LSP partners, wrote off legacy loans, and redirected capital to term loans and warehouse-style lines for other digital-lending NBFCs, plus co-lending arrangements in which both regulated entities hold a share of each loan. In the FY2026 audited results the company reports participating as a "Partner RE" in personal-loan co-lending. 3. **Direct retail lending (from Oct 2025).** Apollo Cash, a fully digital unsecured personal-loan app for blue-collar workers, gig workers and under-banked borrowers, launched around 9 October 2025. By the Q4 FY26 call (12 May 2026), retail loans had risen from 24% to 51% of AUM. ### Business and revenue model | Revenue line (INR M, StockAnalysis restatement of reported financials) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Interest and dividend income (INR M) | 191.67 | 127.78 | 61.05 | 211.69 | 131.2 | | Commissions and fees (INR M) | 496.47 | 299.58 | 113.96 | 84.66 | 59.17 | | Other revenue (INR M) | 12.9 | 16.47 | 24.66 | 6.27 | 16.69 | | Revenue as reported, total income (INR M) | 740 | 461.54 | 210.79 | 304.42 | 212.46 | The mix illustrates the business-model shift. In FY2022, fee and commission income from the LSP model was about two-thirds of reported revenue; by FY2026 interest income dominated and fees had fallen by roughly 88% from their peak. Revenue is essentially 100% financial-services income (interest, processing fees, partner fees). There is no product-sale, subscription or licensing revenue disclosed separately, although the company historically marketed "Software-as-a-Service" (Sonic LMS and APIs) and "Collection-as-a-Service" offerings to partners; any software revenue is not separately disclosed. ### Value-chain position Apollo sits at the regulated balance-sheet layer of India's digital-credit value chain. Upstream it raises equity (internally generated) and modest debt (NCDs, bank/financial-institution borrowing). Midstream it provides the licence, compliance, loan-management system and underwriting engine. Downstream, distribution is either outsourced to fintech partners/NBFCs (B2B2C) or, since October 2025, owned directly through the Apollo Cash app (B2C). ### Customers and end-markets | Customer type | Description | Channel | |---|---|---| | Digital-lending NBFCs | Term loans, warehouse term loans and co-lending | Direct B2B | | Unregulated fintechs / LSPs | Historical on-book lending via partners (named examples in the Q4 FY24 call: OKCredit, Jar) | B2B2C | | Retail borrowers (salaried low-income, blue-collar, gig workers, under-banked) | Small unsecured personal loans via Apollo Cash | Direct B2C app | | Co-lending partner customers | Personal loans co-originated with partner REs | B2B2C | End-market: Indian unsecured consumer credit, primarily small-ticket digital personal loans; secondary exposure to MSME/merchant credit through partners. All revenue is domestic. ### Company self-description (paraphrased, FY2025 Directors' Report) The FY2025 Directors' Report presents Apollo, incorporated in 1985, as a leading fintech-space player led by Mikhil Innani and Diksha Nangia, built on a robust technology stack and committed to making financial services accessible to all. It credits company culture with allowing rapid adaptation to the post-DLG environment and states that a "three lines of defence" risk-management model has been implemented. ### Independent characterisation Stripped of branding, Apollo is a sub-₹110 Cr balance-sheet NBFC with strong in-house engineering, a promoter-family owner, and a history of extracting high returns from a regulatory grey zone (FLDG-backed LSP lending) that RBI subsequently closed. Its FY2024–FY2026 earnings were held up by low-risk wholesale lending to other NBFCs, which carried low credit cost but thin, competitive margins. Apollo Cash is a strategic attempt to capture the full borrower margin, but it re-exposes the company to unsecured retail credit risk, customer-acquisition cost and conduct/collection regulation at a time when RBI is actively scrutinising high-APR lending. The company is closer to a venture-stage fintech lender embedded in an old listed shell than to a mature NBFC franchise.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1985
Mumbai, India
APM

APM Industries Limited

Premium
Information Technology

APM Industries Limited is a single-plant, single-segment Indian spinner of man-made fibre (MMF) yarns. It belongs to the Delhi-based Rajgarhia Group. From one integrated mill at Bhiwadi, Rajasthan, operating under the Orient Syntex name, it converts polyester and viscose staple fibre into fibre-dyed and grey blended spun yarns in the 8s to 40s count range. Output is supplied as single autoconed spliced yarn and as two-for-one (TFO) doubled yarn, with a small sewing-thread line alongside. Installed capacity is about 55,584 spindles, or roughly 18 million kg of yarn a year. The company is a micro-cap with revenue of about INR 270 crore. It is promoter-controlled (about two-thirds held by the Rajgarhia family and affiliates), almost free of net debt, and trades well below book value. Its economics depend on fibre-to-yarn spreads in a cyclical, oversupplied domestic MMF yarn market. Profitability collapsed after FY2023 and is only now tentatively recovering. --- ### Company's own description In the FY2025 Directors' Report, the company says it makes man-made fibre spun yarn and operates in one segment only. Exchange-filed profiles describe the business as the manufacture and sale of man-made fibre spun yarn and sewing thread. The FY2025 report attributes the year's 2% revenue decline and small net loss mainly to weak demand in both the domestic and export markets. ### Independent characterisation | Dimension | Characterisation | |---|---| | Business model | B2B manufacturing; make-to-order and make-to-stock yarn sold by weight (per kg) | | Revenue model mix | About 100% product sales. No meaningful service, subscription or licensing revenue. Small "other operating revenue" (likely waste/scrap sales and export incentives; not separately verified). Other income was INR 13.1 m in FY2025 (Directors' Report FY2025). | | Value-chain position | Mid-stream: Fibre (PSF/VSF) → Yarn (APM) → Fabric (weavers/knitters) → Garments/Home textiles → Brands/Retail | | Customer types | Powerloom and shuttleless weavers, knitters, fabric processors, and yarn traders/agents in India; export buyers | | End-markets | PV (polyester-viscose) suiting and shirting, uniforms and school-wear, fashion fabrics, furnishing, and sewing thread for garmenting | | Geographic exposure | Predominantly domestic India, with some exports (management cites "export demand" as a driver). | | Key inputs | PSF, VSF, dyes/chemicals, power (grid, captive and rooftop/solar), labour | | Operating levers | Spindle utilisation, count mix (finer counts and fibre-dyed yarns earn higher value per kg), power cost, and fibre-price lag effects on inventory | APM is a pure-play intermediate-goods converter in the textile value chain. It buys polyester staple fibre (PSF) from petrochemical producers and viscose staple fibre (VSF), mainly from India's dominant VSF supplier. It blends, dyes at fibre stage, cards, draws, spins, winds and, where required, doubles these fibres into yarn. The yarn is sold to weavers and knitters, who make fabric for suiting, shirting, uniforms, furnishing and similar end-uses. Value is created through the conversion spread (yarn realisation minus fibre cost), less power, labour and other conversion costs. ### Revenue scale (company-reported) | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Revenue from operations (INR lakh) | 29985 | 29400 | 27031 | | Net profit / (loss) (INR lakh) | 417 | -61 | -266 | Sources: Directors' Report FY2025 (FY2024–FY2025); FY2026 audited results, board meeting of 27 May 2026 (via ScanX).

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1973
District Alwar, India
Aplus

Aplus Asset Advisor Co. Ltd

Premium
Information Technology

A Plus Asset Advisor is an independent insurance general agency (GA): a corporate insurance agency that is not owned by any insurer. It distributes life and non-life policies from roughly 34–35 partner insurers through a contracted salesforce that reached 8,897 planners in mid-2026. It was the first GA to list on KOSPI (2020). It earns commissions from insurers rather than underwriting risk, which makes it a capital-light, fee-based distributor. Its economics are therefore driven by planner headcount, productivity, contract persistency and commission regulation. Around this core the founder built a "Total Life Care" group: funeral and pre-need services (A+Life), real-estate brokerage (A+Realty), healthcare services, IT, and, since 2023, KOSDAQ-listed diagnostics maker Nanoentek. Revenue grew from KRW 258bn (FY2021) to KRW 682.5bn (FY2025). Since late 2025, governance has been the main investment debate. Activist Align Partners now owns about 21% and is pressing for refocus on the core GA business, disposal of non-core assets and board independence [S1][S7][S10][S12]. --- ### What the company does A Plus Asset Advisor is a corporate insurance agency (법인보험대리점, GA). Insurers pay it commissions to sell their products through planners registered to the company. Unlike an insurer's captive (exclusive) salesforce, a GA can sell competing products from many carriers. That lets it present side-by-side comparisons to customers, which is the core of its "insurance department store" positioning. At its 2020 IPO the company said it compared and sold products from 35 insurers. It reported approximately 1.09 million customers and about 1.88 million in-force contracts excluding auto insurance (August 2020) [S21]. Later descriptions cite 34 partner insurers across life and non-life lines [S36]. The company's own self-description in Korean disclosures, as summarised by data providers, has three parts: an independent sales platform not tied to any carrier, a nationwide planner network, and an extension into comprehensive asset-management advice [S1]. An offer document cited in coverage of the 2025 tender offer describes the company's role as comparing products' coverage, expense loadings, investment returns and prices from the customer's point of view, and placing them through its planners on consignment from partner insurers [S10]. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely commission/fee revenue from insurers. Product sales (diagnostic devices via Nanoentek) and service fees (funeral, real-estate brokerage) are a minority. | | Product vs. service vs. subscription vs. licensing | Service (distribution commissions) dominates. Product revenue arrived with Nanoentek's consolidation from FY2024. Pre-need funeral contracts at A+Life have a subscription-like instalment structure. No licensing revenue identified. | | Commission structure | Upfront (first-year) acquisition commissions, renewal/maintenance commissions, and insurer performance incentives ("시책"). These are subject to the "1,200% rule", which caps first-year commission at 12× the monthly premium. The cap has applied to insurer-to-GA payments since 2021, and from 1 July 2026 also to GA-to-planner payments [S23]. | | Cost structure | Commissions paid out to planners are the dominant expense. Valueline's breakdown shows FY2025 selling, general and administrative expenses (SG&A) of KRW 653bn against revenue of KRW 682.5bn [S4]. | | Capital intensity | Low. Investment needs are mainly IT (sales-support systems), branch fit-outs, leases and planner recruitment incentives. | | Revenue recognition sensitivity | Brokers note that under the 1,200% rule part of the revenue is deferred, while some selling costs are recognised when paid. This mismatch made reported operating profit volatile after 2021 [S24]. | ### Value chain position The company sits in the distribution link of Korea's insurance value chain: - Insurers (manufacturers) develop and underwrite products. - GAs and other channels (captive agents, bancassurance, telemarketing, online) sell them. The industry calls the separation of product manufacturing and sales "제판분리". Large insurers have increasingly spun off their salesforces into subsidiary GAs, Hanwha Life Financial Services being the leading example. This has enlarged the GA channel but also brought insurer-affiliated competitors into it [S26]. ### Customer types and end-markets **Retail households:** the core market, buying protection products (whole life, critical illness, health, cancer, dementia, children's insurance) and savings and pension products. **Partner insurers:** effectively the company's revenue counterparties (34–35 life and non-life carriers). **Group / non-core end-markets:** funeral and pre-need (A+Life); senior care (A+ Hyodam Lifecare); real-estate brokerage and investment (A+Realty); healthcare services (AAI Healthcare); diagnostics and life-science instruments, sold mostly abroad (Nanoentek); IT and digital (Fine Lab); and loan brokerage (A+ Mortgage) [S18]. ### Independent characterisation Stripped of the "Total Life Care" branding, the group is a mid-sized, high-growth, regulation-sensitive insurance distributor with a conglomerate overlay. In FY2025 the parent GA generated about 88% of consolidated revenue (separate revenue KRW 601.3bn vs. consolidated KRW 682.5bn) [S2][S1]. Non-GA subsidiaries added a net KRW 3.3bn to consolidated profit in FY2025 (separate net income KRW 21.3bn; consolidated KRW 24.6bn) [S17]. However, they absorb meaningful capital: non-controlling interests of KRW 91.5bn sit on the balance sheet, largely reflecting Nanoentek's outside shareholders [S5]. The investment case therefore rests on three things: GA planner productivity, how the business absorbs commission regulation, and capital allocation and governance. The activist campaign of 2025–26 targets exactly that last point.

RevenueN/A
Employees8,897
Market CapN/A
Founded2007
United States, North America
Aplab

Aplab Limited

Premium
Information Technology

Aplab is a sixty-year-old Indian power-electronics and instrumentation micro-cap whose institutional identity was shaped by its founder, P.S. Deodhar, a former Chairman of the Government of India's Electronics Commission and electronics adviser to Prime Minister Rajiv Gandhi. Today it is a ~INR 58 Cr revenue business organised around four management groups: Power Control and Conversion Electronics (UPS, frequency converters, military-grade aviation ground power units), Test and Measurement Instrumentation (LONAR programmable AC sources, VSP/XSP programmable DC sources), Banking and Business Automation (AI-enabled passbook kiosks), and Customer Service and Support. Its competitive claim rests on breadth of a niche portfolio, domestic defence relationships and an in-house pan-India service network. After a decade of losses, negative net worth and statutory-dues stress, the company restored positive net worth via promoter loan conversion (2023) and a partly paid rights issue (2025), reported its best recent profit in FY2026 (PAT INR 2.52 Cr), and has since swung back to a loss in Q1 FY2027 amid a near-complete leadership transition. --- **What the company does.** Aplab designs, manufactures, sells and services professional electronic equipment. Its FY2025 and FY2026 Directors' Reports describe a reorganisation into four business groups: (1) Power Control and Conversion Electronics (PCCE); (2) Test and Measurement Instrumentation (TMI); (3) Banking and Business Automation (BA); and (4) Customer Service and Support (SS). For statutory segment reporting under Ind AS 108, however, the company continues to report a single segment; its Q1 FY2026 results notes describe the business as the manufacture and provision of business-continuity and automation products falling within one segment (Trendlyne results notes, 30 Jun 2025). **Company's own description (paraphrased from the FY2026 Directors' Report).** Management characterises FY2026 as the start of a multi-year transformation in which AI is being used to rationalise processes and monitoring, resources are being concentrated on high-impact initiatives, and non-strategic processes are being eliminated so the organisation becomes leaner and more resilient. PCCE comprises the Nonstop Performance Series® UPS and emergency power systems, frequency converters, automatic changeover switches, power-conditioning equipment, isolation transformers and power-monitoring software, plus KAAS Series military-grade aviation ground power units and KW Series high-power battery chargers. TMI comprises LONAR programmable AC sources, VSP programmable DC sources, high-power linear supplies and the new XSP Series. BA covers self-service passbook kiosks. SS covers after-sales technical and product support. **Business model and revenue model.** **Value-chain position.** Aplab is an original equipment manufacturer and system integrator: it performs in-house design (power-stage and control electronics, firmware, software toolkits), procures semiconductors and magnetics (with historic dependence on imported microcontrollers and DSPs, per FY2023 MD&A), assembles and tests in Maharashtra, and provides long-tail field support. It does not manufacture semiconductors. **Customer types and end-markets.** **Independent characterisation.** Aplab is best understood as a sub-scale, founder-legacy engineering house with genuinely differentiated niche capabilities (programmable AC sources, military 400 Hz ground power, AI passbook kiosks) but chronically constrained by working capital, small order sizes and customer concentration. Its revenue line (INR 49–64 Cr over FY2022–FY2026) is roughly half its FY2014 level (INR 95.16 Cr), and profitability in most recent years has depended on other income or tax credits rather than operating earnings. FY2026 is the first year in the series in which reported operating margin, interest coverage and leverage all improved simultaneously, but Q1 FY2027 (revenue −37.8% YoY, net loss INR 2.52 Cr) shows how fragile that improvement is.

Revenue$0.0B
Employees152
Market CapN/A
Founded1962
United States, North America
HLBPep

HLB Pep Co., Ltd.

Premium
Information Technology

### Key Facts | Item | Detail | Source | |---|---|---| | Current legal name | HLB Pep Co., Ltd. (HLB펩 주식회사) | Biospectator, 1 Apr 2025; Dealsite, 1 Apr 2025 | | Former name | Anygen Co., Ltd. (애니젠 주식회사) | Biospectator; Hankyung, 31 Mar 2026 | | Origin of former name | Taken from Samsung's "Anycall" handset brand at founding. A promised Samsung investment was later withdrawn because of investment regulations. | Hankyung, 31 Mar 2026 | | Founded | 2000 | PatSnap; CB Insights; company IR deck, May 2025 | | Founder | Dr. Kim Jae-il, then a professor at GIST's School of Life Sciences | Hankyung, 31 Mar 2026 | | Incorporation jurisdiction | Republic of Korea | Investing.com profile | | Headquarters | Gwangju, South Korea. | Investing.com; Asia Economy, 30 Jun 2026 | | Exchange / ticker | KOSDAQ (Korea Exchange) / 196300 | KRX data via StockHub | | Listing route and date | Technology-growth special listing (기술특례). The Korea IR Council report gives December 2016; Aju News gives November 2016. | Korea IR Council, 26 Jun 2024; Aju News, 8 Dec 2021 | | Par value | KRW 500 per share | Aju News, 8 Dec 2021 | | ISIN / CUSIP | check digit not confirmed). No CUSIP; not US-listed. | — | | Fiscal year end | 31 December | Butler (DART aggregation) | | Employees (latest and 3-year trend) | — | — | | Auditor | — | — | | Market capitalisation | About KRW 41.0bn at KRW 4,320/share (latest Butler quote). About KRW 44.3bn at KRW 4,665 on 12 Oct 2026 (StockHub). | Butler; StockHub | | Implied shares outstanding | About 9.5 million (derived: market cap ÷ share price) | Derived | | Controlling shareholder | HLB Genex Co., Ltd. (HLB제넥스) and related parties: 42.46% after an August 2026 report, down from 42.70% | DART large-shareholding report, 20 Aug 2026, via StockHub | | Ultimate group | HLB Group, chaired by Jin Yang-gon. HLB Pep is the group's 11th listed affiliate. | Smart Today, 10 Mar 2025 | | Website | Legacy: http://www.anygen.com. | Input list | | Management structure | Co-CEO structure from 31 March 2025: Shim Kyung-jae (management) and Kim Jae-il (business). By March 2026 Kim Jae-il was described as CTO. | Dealsite, 1 Apr 2025; Hankyung, 31 Mar 2026 | | Listing status flag | Designated an administrative-issue stock (관리종목) in March 2025. The trigger was pre-tax continuing-operations loss (법차손) above 50% of equity. | Bizwatch, 31 Mar 2025; Dailypharm | HLB Pep, formerly Anygen, is Korea's pioneer specialist in synthetic peptides. **Manufacturing base:** It says it is the only Korean company with peptide-dedicated GMP facilities for active pharmaceutical ingredients (APIs). It runs two plants: - Jangseong, South Jeolla. GMP-certified in 2011, the first in Korea. - Osong, North Chungcheong. GMP-certified in 2020. **Scale and revenue:** It makes more than 5,000 peptides a year across GMP and non-GMP grades. Revenue comes from custom and research peptides, CDMO work, generic peptide APIs (ganirelix, vasopressin) and a chemical library. **Pipeline:** A long-dated drug pipeline spans oncology, infection, metabolic disease and inflammation. **Ownership and funding:** HLB Group took control in March 2025 through about KRW 60bn of equity and convertible bond (CB) financing. This ended years of liquidity strain and a minority-shareholder dispute. **Post-acquisition strategy:** The company is now pursuing: - international API and CDMO sales (Japan, US, Hong Kong); - a peptide cosmetics brand (LABSENN); - a GLP-1/glucagon dual-agonist obesity programme; - a radiopharmaceutical collaboration. **Financial position:** The business is still small (FY2025 revenue KRW 5.0bn) and loss-making. Its valuation is tied to HLB Group sentiment and to a KRW 30bn CB overhang. --- ### What the Company Does HLB Pep designs, synthesises, purifies and supplies peptides — chains of roughly 2 to 50 amino acids — for pharmaceutical, research, cosmetic and industrial uses. Founder Kim Jae-il is credited with helping define that size range in the field (Hankyung, 31 Mar 2026). The business has five lines. 1. **Peptide APIs (GMP).** Manufactures pharmaceutical-grade peptide APIs in MFDS-certified GMP plants. - Ganirelix (an infertility drug API) is supplied domestically. Its product approval was obtained in 2023 (Korea IR Council, 26 Jun 2024). - Vasopressin (an antidiuretic hormone API) was registered on Korea's DMF system in December 2025 and on the US FDA's DMF system in July 2026 (Biospectator, Dec 2025; Finance Scope, 27 Jul 2026; Asia Economy, 20 Aug 2026). 2. **CDMO.** Contract process development and manufacturing for drug developers. Korean peptide drug developers that need domestic GMP supply generally use the company, as Hankyung's March 2026 profile notes. Its first disclosed overseas definitive CDMO contract was signed with Japan's PeptiGrowth on 30 June 2026. 3. **Research, custom and catalogue peptides.** Non-GMP peptides for academia and industry R&D. - Q2 2026 revenue split (Butler, DART-based): CDMO and research peptides 91%, chemical library 9%. 4. **Cosmetic peptide materials and the LABSENN brand.** - Supplies peptide ingredients. - Launched its own derma brand, LABSENN, in 2026. The core ingredient is the patented CMPEP™, a combination of curcumin peptide and marine peptide. - First export: four LABSENN products to Romania, announced 7 October 2026. 5. **Proprietary drug discovery.** AGM-series candidates in oncology, antiviral, antibacterial, metabolic and inflammatory indications. Most are preclinical; AGM-130 reached Phase 1. ### The Company's Own Description In its May 2025 IR deck, the company calls itself Korea's leading peptide materials developer. It sets out three growth engines: - strengthening the core API and CDMO business; - building a cosmetics "cash cow"; - new drug development as "upside potential". At the May 2025 HLB Forum, CEO Shim Kyung-jae said the company's technology had been undervalued because of past management issues, and that HLB's acquisition had resolved its liquidity problems (Biospectator, 22–23 May 2025). ### Independent Characterisation On the evidence available, HLB Pep is best described as a sub-scale peptide CDMO and API supplier with a venture-style pipeline attached. **Revenue trend:** Revenue fell from KRW 10.3bn in FY2021 to KRW 5.0bn in FY2025. **Profitability:** Operating losses were KRW 4.3–7.3bn a year in FY2022–FY2025 — a cost base well above revenue. **Disclosed sales mix:** Dominated by CDMO and research peptides, so commercial API sales of ganirelix and vasopressin are not yet a separately visible revenue driver. **Strategic value:** Its value to HLB Group lies in three things: - domestic peptide GMP capacity, which is scarce; - optionality on the GLP-1 and peptide-drug supply chain; - a platform for group-wide peptide and radiopharmaceutical projects. ### Revenue Model | Revenue type | Description | Disclosed weight | |---|---|---| | Product / contract manufacturing | CDMO, custom and research peptides, GMP APIs | 91% of Q2 2026 revenue (CDMO and research peptides combined) | | Product (catalogue) | Chemical library | 9% of Q2 2026 revenue | | Consumer products | LABSENN cosmetics; launched 2026, first export October 2026 | Not separately disclosed | | Licensing / milestones | No out-licensing revenue identified in sources reviewed | Not identified | | Subscription | Not applicable | — | ### Value Chain Position The company sits upstream as: - a peptide synthesis and purification specialist, using solid-phase (SPPS) and solution-phase (SPS) synthesis (IntuitionLabs profile); - a GMP API manufacturer; - a CDMO for drug developers. It is also building: - a downstream presence in finished consumer cosmetics (LABSENN); - early-stage new drug discovery. ### Customer Types and End-Markets | Customer type | Examples / evidence | |---|---| | Domestic pharma and biotech drug developers | Novacell Technology (described as a long-standing partner on national drug development projects); Cellivery (KRW 0.8bn preclinical supply contract, Sept 2021) | | Overseas biotech | PeptiGrowth (Japan), CDMO contract June 2026 | | Overseas distributors | NovaBridge (Hong Kong), sales and business-development MOU June 2026 | | Research institutions and universities | Research and catalogue peptides; joint work with GIST | | Finished-dose pharma | Ganirelix and vasopressin API buyers. Named customers not disclosed. | | Cosmetics buyers and consumers | Romanian buyer for LABSENN (October 2026); domestic consumers | End-markets served: pharmaceuticals (peptide therapeutics, including the obesity/GLP-1 class, infertility and critical care); biomedical research; regenerative medicine and cell culture (functional peptides via PeptiGrowth); cosmetics.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2000
Gwangju, South Korea
Anuroop

Anuroop Packaging Limited

Premium
Information Technology

Anuroop Packaging Limited is a family-controlled Indian micro-cap that has made corrugated boxes, sheets, liners and kraft rolls since 1995 at a single semi-automatic plant in Wada, in Maharashtra's Palghar district, serving pharmaceutical, stationery, toys, apparel, water-treatment and FMCG customers in the Mumbai–Thane industrial belt. Since FY2018 it has also traded turpentine and dipentene ("gum"). It listed on the BSE SME platform in November 2019 through a INR 2.64 Cr IPO and later raised equity through a rights issue (2021) and a preferential issue (2024). Consolidated revenue peaked at INR 27.85 Cr in FY2024 and fell to INR 15.66 Cr in FY2026. Profitability is driven largely by a wholly owned subsidiary, Sara Solutions, whose business is thinly disclosed. In September 2026 shareholders approved selling the Wada factory undertaking, and the company is entering a strategic transition. At about INR 9 Cr market value, it trades near a quarter of book value with high working-capital intensity, no dividends and no analyst coverage. --- ### Company's own description On its website and in its regulatory summaries, the company describes itself as a Maharashtra-based packaging business that began in 1995 as a private limited company and became a public limited company on 2 July 2017. It makes corrugated boxes, liners, sheets and kraft rolls, and also produces boxes to customer specifications. It says it serves buyers ranging from large corporates to small and mid-size firms, using a workforce of skilled and semi-skilled operators. Since 2017 it has added trading in gum (turpentine and dipentene). It calls itself a preferred vendor for corrugated boxes and describes its plant as semi-automatic, with an ambition to fully automate it (company website "About" page; ICICI Direct and Motilal Oswal company summaries). Screener.in's summary of the FY2025 annual report characterises APL as an ISO-certified maker of corrugated packaging paper and boards. The 2019 SME IPO prospectus placed the business as a corrugated box manufacturer based in Wada, Thane, supplying fixed packaging products (corrugated boxes, sheets, boards) to the pharmaceutical, stationery, metals and water-treatment industries. It also disclosed that the promoters had diversified into a different line of business through a wholly owned subsidiary, Sara Solutions Private Limited. The prospectus flagged that inexperience in that new line was a risk to financial position and profitability (IPO Abridged Prospectus, risk factor 10). ### Business model and revenue model | Revenue stream | Nature | Model | Disclosure status | |---|---|---|---| | Manufactured corrugated packaging (boxes, sheets, liners, kraft rolls) | Product, made-to-order B2B | Per-unit or per-tonne pricing, customised to order; transactional purchase orders | Exact share of revenue not publicly disclosed (Screener.in shows a "manufactured corrugated boxes" revenue-share metric from the standalone annual report, behind a paywall) | | Traded gum (turpentine and dipentene) | Product, trading | Buy-sell trading margin | Share of revenue not publicly disclosed; started FY2017-18 | | Subsidiary revenue (Sara Solutions) | Not clearly described in public sources; MCA classification "other service activities"; one registry profile lists "technical / professional, scientific and technical" | Not disclosed | Inferred to be about 75% of FY2025 consolidated revenue (see Section 4) | | Subscription / licensing | None | — | — | ### Value-chain position In the corrugated value chain (kraft paper mills → corrugated board makers → box converters → brand owners and shippers), Anuroop is a small converter. It buys kraft paper and converts it into corrugated board, boxes and liners at a semi-automatic plant, so it is exposed to kraft paper price swings and has limited pricing power over both mills and large customers. Its trading of gum chemicals is unrelated to packaging and adds commodity-trading exposure. ### Customers and end-markets The IPO-era customer list (ipocentral.in summary of the 2019 prospectus) included Kokuyo Camlin, A.W. Faber-Castell (India), Himalaya Organics, Ion Exchange India, Mattel Toys India and Pepe Jeans London. The website carries a testimonial from Ganga Pharmaceuticals Ltd. End markets are pharmaceuticals, stationery, toys, apparel, water treatment, metals and FMCG (Groww summary). Customer concentration, current top-customer list and order book are not publicly disclosed. ### Independent characterisation Anuroop is effectively two businesses in one listed shell. The first is a sub-scale, labour-intensive corrugated converter at Wada whose standalone revenue fell from INR 13.62 Cr (FY2024) to about INR 4.48 Cr (FY2025). The second is a subsidiary, Sara Solutions, that appears to generate most consolidated revenue and much of its profit, but whose operating model is not described in available public material. Consolidated operating margins of 35–44% (FY2025–Q1 FY2027) are far above what a commodity corrugated converter normally earns (typically high single to low double digits). This suggests the consolidated profit pool is driven by non-packaging activity or by income items not visible in the aggregated data. Investors should treat the "packaging company" label with caution until the subsidiary's activities are clearly disclosed. Shareholders approved selling the Wada factory undertaking on 24 Sep 2026, which, if executed, would remove most of the remaining manufacturing footprint.

Revenue$0.0B
EmployeesN/A
Market Cap$0.0B
Founded1995
District Palghar, India
Anupam

Anupam Rasayan India Limited

Premium
Information Technology

Anupam Rasayan is a Surat-headquartered custom synthesis and manufacturing (CSM) and specialty chemicals company that has spent the past five years converting itself from a predominantly agrochemical-intermediates supplier into a multi-chemistry, multi-geography CDMO platform. Its historic core is multi-step synthesis for global innovator agrochemical, personal-care and pharmaceutical companies from six plants in Gujarat (~30,000 MT installed capacity). Through three acquisitions it has added backward integration into fluorine (Tanfac Industries, 2022), a US manufacturing base serving electronics, resins and defence-adjacent performance materials (Jayhawk Fine Chemicals, Kansas, closed February 2026), and forward integration into finished pharmaceutical dosage forms (Bliss GVS Pharma, control acquired September 2026). Management frames the combined group as a ~INR 4,000 Cr pro forma revenue platform. The investment case rests on contracted LOI/order-book visibility, fluorination and flow-chemistry know-how, and operating leverage on under-utilised acquired assets; the principal offsets are rising leverage, margin dilution, and a rich valuation. --- **Company's own description.** In its exchange press releases (e.g., FY2026 results release of 23 May 2026 and Q1 FY27 release of 14 August 2026) the company describes itself as one of the leading Indian companies engaged in custom synthesis and manufacturing of specialty chemicals, offering multi-step synthesis and complex chemical reaction technologies to a diverse base of Indian and global customers, operating two business verticals: (i) life-science-related specialty chemicals (agrochemicals, personal care, pharmaceuticals) and (ii) other specialty chemicals / performance materials (specialty pigments and dyes, polymer additives, electronics, EV and battery chemicals, polymers). Management's stated ambition, reiterated in Q4 FY26 and Q1 FY27 commentary, is to build a "globally integrated specialty chemicals and CDMO platform." **Business model.** The core model is contract/custom manufacturing: an innovator customer (typically a multinational) transfers or co-develops a molecule (usually an advanced intermediate or active ingredient precursor), Anupam develops and scales the process, and supplies under multi-year purchase agreements or letters of intent (LOIs). Revenue is overwhelmingly product sales (manufactured chemicals sold per kilogram/tonne); there is no material subscription or licensing revenue. Following the Bliss GVS acquisition, a branded-generic formulations business (150+ brands, per acquisition announcement) adds a new revenue type — branded product sales into emerging markets (Africa, Asia, Latin America) and regulated-market supply. **Revenue-model mix (independent characterisation).** Pro forma split per the company's Bliss completion release (29 Sep 2026): standalone INR 1,676 Cr, Tanfac INR 711 Cr, Jayhawk INR 722 Cr, Bliss GVS INR 927 Cr (total ≈ INR 4,036 Cr). **Value-chain position.** Anupam sits in the "N-1 / N-2" position: it manufactures advanced intermediates one or two steps before the final active ingredient, plus some actives. Tanfac moves it upstream into basic fluorine (hydrofluoric acid, potassium fluoride, aluminium fluoride), securing key fluorination inputs. Bliss moves it downstream into finished dosage forms (suppositories, pessaries, tablets, capsules, injectables). Jayhawk adds a US-located N-1 capability for epoxy/polyimide/hybrid-resin additives, electronics and semiconductor materials. **Customer types.** Global innovator agrochemical companies; Japanese, Korean and European chemical and electronics multinationals (polymer intermediates, liquid-crystal intermediates, engineering fluids, semiconductor/data-centre materials); personal-care ingredient majors; pharmaceutical innovators and generics (KSMs, intermediates, and via Bliss, distributors and governments in emerging markets); battery developers (BasqueVolt LOI). In April 2024 the company stated it served over 73 domestic and international customers including 29 multinationals (company press release, 2 April 2024). Named customers are generally not disclosed due to confidentiality; LOI counterparties are typically described only as "a leading Japanese multinational" etc. **End-markets.** Crop protection (55% of standalone FY26 revenue, down from 76% in FY22); pharmaceuticals; personal care; performance materials (polymers/high-performance thermoplastics for aerospace, semiconductor process materials, electronics, liquid crystals, engineering fluids, refrigerants via Tanfac's HFC-32 project); EV / solid-state battery materials; defence and aviation (Jayhawk).

Revenue$0.3B
EmployeesN/A
Market CapN/A
Founded1984
Surat, India
Anterogen.

Anterogen.Co., Ltd.

Premium
Information Technology

Anterogen is a Seoul-based adult stem-cell company. It was among the first organisations anywhere to bring adipose-derived mesenchymal stem cell (ASC) products to market: Queencell, an autologous stromal-vascular-fraction product approved in 2010, and Cupistem, approved in January 2012 for Crohn's fistula and described as the world's first approved ASC therapy. Neither domestic product scaled commercially. Queencell's licence was withdrawn in 2026, and Cupistem now generates negligible sales. Current revenue depends mainly on the in-licensed pulmonary arterial hypertension drug Remodulin. The investment case therefore rests on the company's allogeneic, off-the-shelf, cryopreservable ASC hydrogel sheet platform (ALLO-ASC-Sheet). Japan approved it in April 2026, as "Allostem", for epidermolysis bullosa through licensee Ishin Pharmaceutical. It launched in Japan on 27 July 2026, with Anterogen acting as exclusive manufacturer and supplier. The second major use of the platform, diabetic foot ulcer, has failed two efficacy readouts. Anterogen is a pre-profitability, low-leverage, equity-funded biotech. Its value now hinges on Japanese Allostem uptake and on ex-Japan expansion. --- ### What the company does Anterogen researches, develops, manufactures and sells cell-therapy products and orphan drugs based on adult stem cells, chiefly adipose tissue-derived MSCs. It also sells stem-cell-conditioned-media cosmetics and provides stem-cell banking and analytical testing services. Its commercial and development portfolio has three layers: 1. **Approved autologous cell therapies (Korea).** - Cupistem (autologous ASC injection for Crohn's fistula; MFDS approval January 2012; HIRA reimbursement January 2014). - Queencell (autologous adipose SVF for subcutaneous tissue defects; MFDS approval March 2010; licence withdrawn 2026). - Adipocell (for depressed scars) is cited in company materials as an earlier product. 2. **Allogeneic off-the-shelf platform (ALLO-ASC).** A hydrogel sheet carrying about 1 million donor-derived ASCs per 5×5 cm sheet. It is cryopreservable for about one year and "ready-made" (no patient-specific culture is needed). Applications: - Epidermolysis bullosa (Allostem; approved in Japan in 2026) - Diabetic foot ulcer - Burns - Crohn's disease (injectable) - Knee osteoarthritis (ANT-301) 3. **Non-cell assets.** - In-licensed Remodulin (treprostinil) injection for pulmonary arterial hypertension, which is currently the main revenue source. - A small-molecule herpes zoster antiviral (ANT-501), obtained through the 2022 merger with CSK. - Cosmetics: SCM2 and SCM2-Black hair care; Therastem-Derma, Therastem-White Silk and Therastem-White Glutathione skin care; and a "stem cell media program set" cosmetic raw material. - Services: stem-cell banking, and sample analysis for clinical studies (identity, purity, potency and adventitious-virus testing). ### Business and revenue model | Revenue stream | Model | Status (Oct 2026) | Source | |---|---|---|---| | Remodulin injection | In-licensed product distribution in Korea | Described in June 2026 press as effectively the sole meaningful revenue source | Medisobizanews, 15 Jun 2026 | | Cupistem | Own-product sales; reimbursed (ceiling price KRW 13.49M per treatment, 2014) | Negligible current sales | Biospectator, 2014; Medisobizanews, 2026 | | Queencell | Own-product sales | Licence withdrawn (June 2026) | Medisobizanews, 15 Jun 2026 | | Allostem (ALLO-ASC-EB) supply to Ishin | Finished-product supply, plus milestones and a royalty (about 9% of sales, per 2019 press) | First commercial shipment July 2026 | eToday, 2019; Medical Daily, Jul 2026 | | Licensing income | Upfront and milestone payments from Ishin (EB, DFU and burns licences, Japan/Taiwan) | KRW 3.8bn of upfront and milestones received by c.2016; later milestones NPD | Biospectator, c.2016 | | Cosmetics | Product sales (B2C/B2B), raw material | Ongoing; revenue NPD | Investing.com profile | | Services | Stem-cell banking and analytical testing | Ongoing; revenue NPD | Investing.com profile | **Mix by type.** Product sales (distribution plus own products) dominate. Licensing is episodic. There is no subscription revenue. A product-by-product revenue split for FY2023–FY2025 is NPD in the sources reviewed. **Value-chain position.** For Allostem, Anterogen is a vertically integrated originator and contract manufacturer: - It holds the cell banks. - It manufactures at its Gasan and Magok GMP sites, both accredited by Japan's PMDA as Foreign Manufacturers in March 2025. - It ships finished sheets to Ishin, which holds the Japanese marketing authorisation, carries out commercialisation and holds Taiwan rights. In Korea, the company sells directly and distributes Remodulin. **Customers and end markets.** - Hospitals treating rare and severe dermatological diseases: EB in Japan. - Gastroenterology and colorectal surgery: Crohn's fistula. - Pulmonary hypertension centres: Remodulin. - Wound-care settings: DFU, investigational. - Orthopaedics: osteoarthritis, investigational. - Consumers: cosmetics. In its IR materials the company describes itself as a bio-venture for "human tissue regeneration" specialising in cell therapies and orphan drugs using adult stem cells. Its founder has framed the strategy as targeting niche rare-disease markets in Japan, the US and Europe that lack competitors, rather than large crowded indications (Biospectator interview, c.2016). **Independent characterisation.** Anterogen is best understood as a single-platform, pre-scale rare-disease cell-therapy manufacturer whose domestic legacy products have failed commercially. A thin, low-margin distribution business partially covers fixed costs. The company holds a large equity cushion relative to its liabilities (equity of KRW 87.45bn against total assets of KRW 88.26bn at FY2025), but its operating cash burn is modest and its revenue base is very small. The April 2026 Japanese approval is the company's first ex-Korea commercial validation. Its economic significance depends on uptake in a patient pool estimated at roughly 500–1,000 in Japan.

Revenue$0.0B
Employees35
Market CapN/A
Founded2000
United States, North America
Antarctica

Antarctica Limited

Premium
Information Technology

Antarctica Limited is a four-decade-old Kolkata company that was built as an export-oriented manufacturer of printed paper packaging (folding cartons, tea-bag tags, paper cups, labels and books) with a unit in the Falta Special Economic Zone and a printing unit in Kolkata. From roughly FY2016 that business went into steep decline, with revenue shrinking to below INR 1 crore by FY2023. Between 2024 and 2026 the founding Kuthari family sold down and has now been reclassified out of the promoter category; a new, largely Gujarat-based board took over and repositioned the company as an agricultural produce and commodity trading business run from Ahmedabad. Revenue jumped from INR 0.84 crore (FY2024) to INR 62.91 crore (FY2026) and INR 98.32 crore on a trailing basis, but at razor-thin margins, with negative operating cash flow, a widely held free float of more than 90,000 retail shareholders, a disclaimer of audit opinion and a proposed INR 69 crore rights issue. --- ### What the company does today The FY2026 Annual Report's "State of Company's Affairs" describes a company that "continued to focus on its agriculture business" and was exploring opportunities "across the agricultural value chain", citing demand growth, technology and government initiatives as sector tailwinds. Market-data descriptions (share.market) characterise the business as carton box manufacturing, agricultural activities, commodity trading, label printing, tea bags and other packaging items, a description that blends the legacy and new activities. The most important disclosure for understanding the current model is in Annexure-I of the FY2026 Board's Report, which states that the energy, R&D and technology-absorption disclosures are not applicable because the company "has not involved in manufacturing operations". In other words, as of FY2026 the company self-describes as non-manufacturing. Its revenue is generated from the sale of traded goods. ### The company's own description (legacy) In the FY2023-24 Annual Report (referenced by Screener), the company described itself as "mainly engaged in the manufacturing of carton boxes, label printing, tea bags, and other packaging items", a paper-based packaging and publishing product manufacturer. The legacy product portfolio, as disclosed, comprised folding cartons with inner liners, hard-tag double-chambered tea bags, printed hard tags for high-speed tea-bag making, printed paper and PE-coated cups, and books, brochures, labels and posters with in-house binding and finishing. ### Independent characterisation On the evidence available, Antarctica Limited is best characterised as a listed shell that has been repurposed into a low-margin agri-commodity trading vehicle. The indicators are: (i) the reclassification of the CIN's industry code from printing (22219) to wholesale trade (46695); (ii) FY2025 segment revenue split almost evenly between "Agriculture" (INR 12.84 crore) and "Commodity" (INR 12.66 crore) against INR 0.15 crore from printing; (iii) operating margins collapsing from 20-25% in early quarters of the new business to roughly 0-1.5% as volume scaled; (iv) no manufacturing, no R&D, no exports and a handful of employees; and (v) a capital-raising and enabling-resolution agenda (INR 69 crore rights issue, INR 100 crore section 186 investment/loan headroom, INR 50 crore related-party transaction limit, foreign-investor limit raised to 49%) that is large relative to the company's INR 17 crore net worth. ### Business model and revenue model | Dimension | Assessment | Basis | |---|---|---| | Revenue model | 100% product sales (traded agricultural produce and commodities; residual printing/stationery) | Morningstar profile; FY2025 segment data (Torus Digital) | | Product vs service vs subscription vs licensing | Product: ~100%. Service, subscription, licensing: nil disclosed | FY2026 AR | | Value-chain position | Intermediary/trader between producers or aggregators and buyers; no processing or manufacturing disclosed | FY2026 AR Annexure-I | | Customer types | Not publicly disclosed (no customer concentration data reviewed) | — | | End-markets | Domestic Indian agricultural and commodity markets; legacy packaging for tea, coffee, cosmetics, liquor, spices and pharmaceuticals | FY2026 AR (no export sales); company history | | Geography | 100% India in FY2025 and FY2026 (nil foreign exchange earnings) | FY2026 AR Annexure-I | | Capital intensity | Very low: fixed assets fell from INR 9.03 crore (FY2024) to INR 7.20 crore (FY2026); nil capex in FY2026 | Screener balance sheet and cash flow | | Working capital intensity | High in absolute terms (other assets INR 47.50 crore vs revenue INR 62.91 crore), funded by trade payables/other liabilities and unsecured loans | Screener |

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1982
Ahmedabad, India
Ansal

Ansal Buildwell Limited

Premium
Information Technology

Ansal Buildwell Limited (ABL) is a New Delhi-headquartered real estate developer and construction company. It is controlled by the Gopal Ansal branch of the Ansal family, and the promoter group holds 54.83%. Its business is plotted townships, villas, group housing, builder floors and small commercial complexes. Its footprint centres on Gurugram (Sushant Lok II/III) and on Tier-2 and Tier-3 towns: Amritsar, Pathankot, Jhansi, Jaipur, Gwalior, Kochi and Faridabad. It is a land-bank-monetisation story rather than a growth developer. Revenue has shrunk from INR 187.7 crore in FY2022 to INR 40.4 crore in FY2026, and reported revenue swings sharply from quarter to quarter as plots and units are handed over. The balance sheet is dominated by inventory and customer advances. Gross debt is moderate at INR 49.3 crore. The defining exposure is INR 58.9 crore invested in, and advanced to, its wholly-owned subsidiary Ansal Crown Infrabuild, whose Faridabad project went into insolvency. A third-party resolution plan for that subsidiary was approved in July 2026. The stock trades at roughly 0.46x book value. --- **Company's own description.** ABL's filings say it is in the business of promoting, constructing and developing integrated townships, residential and commercial complexes, multi-storied buildings, flats, houses and apartments (Screener summary citing the annual report). Its notes to accounts classify standalone operations as primarily "Real Estate Development/Construction", which is treated as a single reportable segment (Q1 FY2027 results notes, Aug 2026). Brickwork Ratings, drawing on company information as of April 2021, said ABL was executing projects in Gurugram, Kochi, Amritsar, Jaipur, Faridabad, Gwalior, Pathankot and Jhansi, among other locations. **Business model.** ABL is a vertically integrated "promoter-developer" in the Indian model: 1. It acquires or aggregates land, often through collaboration and joint-development agreements and through subsidiaries. 2. It obtains licences, chiefly town-planning and change-of-land-use approvals in Haryana and Punjab. 3. It sells plots, villas, floors and apartments off-plan, collecting staged customer advances. 4. It carries out development works such as roads, sewerage, water supply and electrification, and builds the structures. 5. It recognises revenue on handover or possession under Ind AS 115. Historically ABL also undertook third-party construction contracts. Named examples are the C-DOT main R&D building at Mehrauli in Delhi, the covering of the Palam Drain in Dwarka, and the Gyan Bharati School building in Saket. It also operates residents' clubs (Club Florence, Club Harmony and Riverdale Club), which generate membership and service income. **Revenue model mix.** No revenue-type split is publicly disclosed. Analytically: - Most revenue is product sales: plots, villas, floors and apartments, recognised at handover. - A small, recurring service component comes from club operations, maintenance and rentals. - Other income of INR 4.2–4.3 crore per year (FY2025–FY2026), mostly interest, is material relative to the business. It made up about 9% of total income in FY2026. - There is no subscription or licensing revenue. **Value-chain position.** ABL is a land-owning developer and builder. It sits upstream of the end buyer and downstream of landowners and contractors. Its edge, to the extent it has one, is legacy land held at historic cost in non-metro locations. **Customer types and end markets.** The customers are mainly individual retail homebuyers and plot investors in mid-income segments, plus small commercial buyers and tenants for shops and offices. The end markets are residential real estate in the NCR (Gurugram and Faridabad), Punjab (Amritsar and Pathankot), Uttar Pradesh (Jhansi), Madhya Pradesh (Gwalior), Rajasthan (Jaipur) and Kerala (Kochi). **Independent characterisation.** ABL is effectively in run-off and monetisation mode. Inventory and work-in-progress were about INR 262.5 crore standalone at FY2025 (May 2025 audited statement of assets and liabilities). That is about 5x the FY2025 revenue base and implies roughly 9,177 inventory days in FY2026 (Screener ratio). The company has not announced a major new launch in the disclosure trail reviewed. Earnings therefore depend on handover timing and on land or bulk sales, not on a pipeline of new projects. The Ansal Crown Infrabuild insolvency removed its largest growth project, Ansal Crown Heights in Faridabad, from its control.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1983
New Delhi, India
Anna

Anna Infrastructures Limited

Premium
Information Technology

Anna Infrastructures Limited is a promoter-controlled micro-cap developer of real estate in Agra, Uttar Pradesh. The Mittal and Agarwal families own 73.19% of the equity. The company began in 1993 as Anna Finance Limited, a non-banking finance company registered with the Reserve Bank of India. It moved into real estate in 2001 and adopted its present name in the mid-2000s. Its developed portfolio is mostly plotted residential colonies, with smaller shop and flat projects: - Plotted colonies: Ikon Residency, Ikon City, Icon Greens and Icon Vatica. - Shops: Anna Complex and Anna Ikon. - Flats: Shivalik Residency. The company also keeps a small loans-and-investments book, a legacy of its finance origins. Several data aggregators classify it as an NBFC rather than a developer for this reason. Scale is very small: FY2026 revenue was INR 1.92 Crore, net profit INR 0.75 Crore and net worth INR 11.41 Crore. The balance sheet has had no debt since FY2024. Revenue is lumpy and depends on individual plot sales. Its investment profile is that of an asset-backed, illiquid, closely held land holder rather than an operating growth developer. --- ### The company's own description The Directors' Report in Annual Report FY2023-24 states: - The company is engaged in "Lands for Real Estate Development". - It develops residential, commercial and social infrastructure projects. - There was no change in the nature of business during the year. The company website gives the objects clause as follows: to carry on business as real estate developers, builders, contractors and colonizers, and in other activity relating to construction of buildings, roads and highways. Screener's summary of the annual report adds that the company also deals in loans and investments alongside development. ### Independent characterisation Anna Infrastructures has three economic components. **1. Plotted land development and sale (core).** - The company acquires land in and around Agra, subdivides it into residential plots and sells them. - It also sells a limited number of commercial shops and flats. - Revenue is recognised on sale or registration. That makes reported quarterly revenue highly uneven. For example: - Q4 FY2025 revenue was INR 1.27 Crore, against INR 0.11–0.30 Crore in each of the three previous quarters. - Q3 FY2026 revenue was INR 1.73 Crore; Q4 FY2026 revenue was INR 0.04 Crore (Screener quarterly data). **2. Loans and advances (legacy finance activity).** - The company was registered as an NBFC at inception (IIFL, Kotak). - Interest income from loans given is part of revenue. Screener's data model treats the company under its "financing profit" format and classifies it in the NBFC industry. - The exact split between property sales and interest income is not available from accessible sources. Screener lists "Interest Income from Loans" and "Real Estate Sales (by Project)" as extracted line items, but the values are behind a paywall. **3. Treasury investments.** - Non-current investments were nil until FY2023. They then rose to INR 0.50 Crore (FY2024), INR 1.34 Crore (FY2025) and INR 4.41 Crore (FY2026) (Screener standalone balance sheet). - Screener lists "Mutual Fund Investments (Fair Value)" as a tracked line item. This indicates surplus cash from project sales is being placed in mutual funds. - Other income rose from INR 0.06 Crore (FY2022) to INR 0.23 Crore (FY2026) and INR 0.32 Crore on a trailing-twelve-month basis. ### Revenue model mix | Revenue type | Share of revenue | Comment | |---|---|---| | Product (sale of plots, shops, flats) | Majority (estimated; exact % not publicly disclosed) | Recognised on transfer; lumpy | | Interest on loans given | Minority (exact % not publicly disclosed) | Legacy finance activity | | Subscription / licensing | None | — | | Rental / annuity | Not publicly disclosed | The MD&A refers to "investment and development properties" producing steady cash flows. No rental income line was located in accessible sources. | ### Value chain position - The company is a land aggregator and colonizer. - The FY2023-24 MD&A says it operates an outsourcing model, appointing external architects and contractors rather than building in-house. It describes these as "globally renowned". - It has no disclosed construction subsidiary, materials business or brokerage arm. - Marketing is done in-house. The FY2023-24 MD&A says the company "is setting up a good marketing team" to increase turnover. ### Customer types and end-markets **Customers:** Individual retail buyers of residential plots and flats, plus small-business buyers of commercial shops in Agra and nearby areas. No institutional or government customers are disclosed. **End-market:** Residential and small-format commercial real estate in a Tier-2 city (Agra, Uttar Pradesh). Company summaries cite projects "in and around Delhi and Agra" (IIFL, Kotak); no Delhi-NCR project is named. **Concentration:** Customer concentration is not disclosed. Given the revenue scale, a few transactions can make up a full year's revenue.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1993
Agra, India
Anjani

Anjani Portland Cement Limited

Premium
Information Technology

Anjani Portland Cement is a micro-cap, south-Indian integrated cement producer controlled by the Chettinad Group, operating a 1.16 MTPA integrated plant at Suryapet, Telangana, and — through its 51.09%-owned subsidiary Bhavya Cements — a 1.4 MTPA integrated plant at Tangeda, Andhra Pradesh, for a group-consolidated capacity of about 2.6 MTPA. It sells Ordinary Portland, Portland Pozzolana, rapid-hardening and specialty cements to dealers, builders and institutional buyers in Telangana, Andhra Pradesh and adjacent southern states, supported by captive limestone mines and a 16 MW captive thermal power plant. After a debt-funded acquisition of Bhavya in 2021, the company slipped into four consecutive years of consolidated losses (FY2023–FY2026) as southern overcapacity crushed realisations. Management and the parent have since engineered a balance-sheet reset — selling 48% of Bhavya to the parent for INR 254 crore in December 2025 — and in June 2026 began migrating the "Anjani" and "Bhavya" brands to "Chettinad," making the listed entity an increasingly integrated satellite of its parent. --- **What the company does.** Anjani Portland Cement (APCL) manufactures and sells grey cement and, to a much smaller extent, trades cement procured from other producers. It reports two operating segments: (i) manufacture of cement, and (ii) generation of power. The power segment is effectively captive — in FY2026 its entire INR 2,468 lakh of segment revenue was eliminated as inter-segment revenue, meaning all external revenue comes from cement (NSE Q4/FY2026 filing, 27-May-2026). **Company's own description.** In its exchange filings and annual reports, the company describes itself as engaged in manufacturing and selling cement, with a cement production capacity of 12 lakh MT per annum at the standalone level, and as a subsidiary of Chettinad Cement Corporation. Screener's summary of the FY2023 annual report characterises the company as a manufacturer of high-quality premium cement that is part of the Chettinad group, with a business network across Tamil Nadu, Odisha and Karnataka and more recent entry into Maharashtra, Kerala and Goa. **Independent characterisation.** APCL is best understood as a regional, price-taking, commodity cement producer with a structural cost disadvantage of sub-scale plants, operating in the most oversupplied cement region of India. Its strategic value lies less in standalone economics than in (a) captive limestone reserves (three mines within 2–8 km of the Suryapet plant; two adjacent mines at Bhavya), (b) its role as the Chettinad group's Telangana/Andhra Pradesh supply node, and (c) its listed status. Since FY2023 the company has run at negative or thin EBITDA and has relied on parent inter-corporate deposits (ICDs) for liquidity. The December 2025 sale of 48% of Bhavya to the parent and the June 2026 brand harmonisation indicate a progressive operational merger into Chettinad's marketing and distribution system. **Business model and revenue model.** **Value-chain position.** Fully integrated upstream — limestone mining → clinkerisation → grinding → bagging → dispatch — with partial captive power. Downstream, the company sells through a dealer/distributor network and to non-trade customers (builders, contractors, government projects). It does not operate ready-mix concrete plants at scale. **Customer types.** Trade (retail via dealers, mainly individual home builders) and non-trade (real-estate developers, infrastructure contractors, government projects); per Investing.com's profile, commercial, private, trade/non-trade, government and retail customers. Customer concentration: not publicly disclosed, though related-party sales to CCCPL have become material (shareholders approved material related-party transactions with CCCPL of up to INR 1,000 crore in December 2025). **End-markets.** Individual housing (the dominant end-use in south India), urban infrastructure, irrigation and road projects in Telangana and Andhra Pradesh, plus railway applications (Bhavya manufactures sleeper-grade OPC).

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1983
Hyderabad, India
Aniplus

Aniplus Inc.

Premium
Information Technology

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Employees (parent, persons) | 39 | 44 | 60 | 54 | 51 | | Average salary (KRW M) | 43.44 | 51.45 | 53.49 | 60.13 | 63.40 | | Revenue per employee (separate, KRW 100M) | 5.2 | 6.7 | 6.3 | 7.0 | 8.4 | [DART business reports FY2021–FY2025 via ETF Shopping] Aniplus is Korea's dominant importer and multi-channel monetiser of Japanese "youth" animation (anime). It licenses most new Japanese TV anime each season: the H1 2026 semi-annual report says 70–80% of titles produced in Japan per quarter. It then monetises each title along a vertically integrated chain: its own pay-TV channels (ANIPLUS and Animax), its 100%-owned anime streaming platform Laftel, VOD sub-licensing to IPTV and global OTT platforms, theatrical distribution, merchandise retail, collaboration cafés, and the AGF fan festival. Around this anime core it runs adjacent businesses: art and photo exhibitions (Media & Art), K-drama production (WeMad), fandom-goods fulfilment (Rowoon Company C&C), and Southeast Asian channel distribution through its Singapore subsidiary (Plus Media Networks Asia). The model is an IP-licensing and distribution model, not a studio model, so earnings depend heavily on the strength of each season's slate and on blockbuster theatrical releases. In 2026 management is repositioning the group around Laftel as an online/offline fandom platform, just as Sony-owned Crunchyroll enters Korea directly. --- ### The company's own description (paraphrased) In its disclosures and investor communications, Aniplus describes itself as a global animation content company. It imports Japanese anime IP, airs it on its own TV channels, streams it on Laftel, sells domestic rights to IPTV VOD services and global OTT platforms such as Netflix, distributes theatrical anime films to cinemas, and supplies additional-rights titles to Southeast Asia through PMNA and Laftel [DS Investment initiation, 21 Aug 2025, as reported by SmartToday]. Following the July 2026 merger of Animax Broadcasting Korea, the company describes a single value chain from IP rights acquisition and channel operation to OTT streaming, with stated plans to add in-house production, a larger online store, and a portal service [company release via SmartToday/Segye, 30 Jun 2026]. ### Independent characterisation Economically, Aniplus is a rights aggregator with captive distribution. Its main asset is a recurring, high-share position in the Korean licensing market for Japanese anime. Each season it buys Korean (and for some titles, wider Asian) rights and recovers the cost several times over through: 1. **Broadcast:** ANIPLUS and Animax pay-TV channels earn carriage and advertising revenue. In 2025 ANIPLUS ranked first by annual ratings among anime/kids channels for the first time since launch, and the two channels together held about 27% viewing share [company statement via CB Insights news feed, Dec 2025]. 2. **Streaming (B2C):** Laftel subscriptions. Laftel is Korea's largest anime OTT, and the press describes it as the only consistently profitable domestic OTT [SmartToday, Nov 2025]. 3. **Licensing (B2B):** sub-licensing VOD and streaming windows to IPTV operators and global OTT platforms. Netflix and Coupang Play are named as buyers [Financial News, May 2021]. 4. **Theatrical:** cinema distribution of anime films. *Attack on Titan: The Last Attack* (Mar 2025) and *Demon Slayer: Infinity Castle* (Aug 2025) were the 2025 drivers [SmartToday; Segye]. 5. **Merchandise and experiences:** Aniplus Shop stores, collaboration cafés, online goods sales, and AGF (Anime x Game Festival), Korea's largest anime/game fan festival, extended to three days in 2025 [SmartToday, Nov 2025]. 6. **Adjacencies:** exhibitions (Media & Art), drama production (WeMad), fandom-goods solutions (Rowoon Company C&C), and SEA channels (PMNA: ANIPLUS Asia, K-PLUS). ### Revenue model mix | Revenue type (share of consolidated revenue) | 3Q 2020 | 1Q 2023 | 2Q 2026 | |---|---|---|---| | Content (broadcast, licensing, streaming, theatrical) % | 79 | 67 | 62 | | Merchandise / goods % | 14 | 21 | 20 | | Exhibitions, events, drama, other % | 7 | 13 | 18 | [SK Securities, Feb 2021 (3Q20 mix); Sangsangin Securities via Asia Economy, Jun 2023 (1Q23 mix); Butler (2Q26 mix, from DART)] Note: the three periods come from different sources, and category definitions may not be identical. ### Value-chain position, customers, end-markets **Upstream:** Japanese production committees and licensors. Licensors are not individually named in reviewed sources. Aniplus is a licensee, not an IP owner, for most of its catalogue (see Risk Section 18). **Midstream:** Aniplus/Animax rights management, subtitling and localisation, channel operations, theatrical distribution. **Downstream customers:** (a) consumers (Laftel subscribers, shop and café visitors, AGF and exhibition ticket buyers); (b) platforms (IPTV operators, Netflix, Coupang Play, Chinese OTTs iQIYI, Bilibili and Tencent via PMNA); (c) cinemas (e.g., Megabox for the exclusive *Attack on Titan* release); (d) pay-TV platforms (channel carriage); (e) B2B goods clients for Rowoon (e.g., the virtual idol PLAVE's official store, Smilegate, Aladin). **End-markets:** the Korean animation, OTT and pay-TV markets; Korean character/merchandise retail; Korean exhibitions; Southeast Asian pay-TV and OTT (Singapore, Hong Kong, Philippines, Malaysia); and selectively Japan (exhibitions). **Core audience:** teens to adults in the "subculture" fandom. SK Securities (2021) identified a core audience aged 15+ "mania" viewers.

RevenueN/A
Employees51
Market CapN/A
Founded2018
United States, North America
AngelFibers

Angel Fibers Limited

Premium
Information Technology

Angel Fibers Limited is a single-plant, single-product cotton spinner located in the Saurashtra cotton belt of Gujarat. It converts raw cotton into 100% cotton, ring-spun, grey single yarn — carded, combed and compact varieties in the Ne 20s–50s count range — sold to knitters, weavers and yarn merchants/exporters, and monetises spinning by-products (flat waste, comber noil) as cotton waste. With 39,648 installed spindles across two units at Haripar (Jamnagar district), annual revenue of INR 211.5 Cr (FY2026) and a market value near INR 25 Cr, it is a price-taking micro-cap in a fragmented, commodity-driven industry. Since a 2020 change of control to the Ranipa–Raiyani promoter group, management has prioritised deleveraging (total debt down ~49% from FY2022 to FY2026) over growth capex. The investment case rests on balance-sheet repair and cotton-yarn spread cyclicality; the key constraints are razor-thin margins, high related-party trading intensity, a 28.7% promoter pledge and an ageing asset base. --- ### What the company does Angel Fibers is a primary cotton spinning mill. Its principal line of business, as described in its own filings and repeated in exchange-hosted company summaries (IIFL / Capitaline company profile), is the manufacturing and spinning of cotton yarns. It operates two spinning units at a single site in Kalavad taluka, Jamnagar district, Gujarat — close to the cotton-growing areas of Saurashtra and Maharashtra — with installed capacity of 39,648 spindles: Unit 1 of 19,584 spindles (commissioned in FY2015-16 with installed capacity of 4,363 MT per annum) and Unit 2 of 20,064 spindles. The company also trades in cotton waste, a by-product of its spinning operations. ### Company's own description The company's descriptor (as reproduced on Screener from its annual report) characterises it as a manufacturer and supplier of premium-quality ultra-fine knitting yarn made from 100% cotton — ring-spun, grey, single yarn in counts Ne 20s to Ne 50s, in combed and carded (compact) forms, for knitting and weaving. IPO-era materials described the yarn as used in knitted shirts, sheeting, bed sheets and socks, and stated that the company served both global and domestic markets. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | ~100% product revenue (manufactured yarn plus by-product waste sales). No service, subscription or licensing revenue. | | Pricing | Spot/contract commodity pricing; yarn prices track cotton (Shankar-6 / CCI auction) prices with a variable "spread". The company is a price-taker. | | Cost structure (FY2026) | Raw-material consumption INR 171.54 Cr = 81.1% of revenue; other expenses (power, stores, freight) INR 22.27 Cr = 10.5%; employee cost INR 8.79 Cr = 4.2%; depreciation INR 5.43 Cr = 2.6% | | Value-chain position | Upstream-midstream: raw cotton (ginned lint) → yarn. Sits between ginners/CCI and knitters/weavers/garment exporters. | | Customer types | Direct knitters and weavers; yarn traders and merchant exporters; related-party entities (Redeco Fibers Pvt Ltd, Haripriya Spinning Mill Pvt Ltd, Murlidhar Worldtrade Pvt Ltd) under shareholder-approved material RPT limits | | End-markets | Knitted apparel (T-shirts, hosiery), woven fabrics, home textiles (sheeting, bed linen), socks — both domestic and (indirectly or directly) export | ### Independent characterisation Angel Fibers is best understood as a cotton-spread trading business with a fixed-cost manufacturing wrapper. Gross margin (revenue less materials and inventory change) has been remarkably stable at 18–21% across FY2022–FY2026, but this gross margin must absorb power, stores, freight, labour and depreciation; EBITDA margin has consequently oscillated between 3.6% and 8.3%. Reported profitability is materially supported by other income (INR 4.5–5.7 Cr per year, likely including government incentives/interest subsidies typical of Gujarat textile policy — the composition is not publicly itemised in sources reviewed), which in FY2026 exceeded the company's entire profit before tax. The business is therefore highly sensitive to (a) the cotton–yarn spread, (b) capacity utilisation, and (c) continuation of non-operating income streams. A note on a data conflict: the ROIC.ai company description labels Angel Fibers a "100% export-oriented unit" with 19,584 spindles. This appears to reflect pre-expansion IPO-era information and conflicts with the company's own disclosures of 39,648 spindles and of both domestic and export sales.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2014
Dist.: Jamnagar, India
AngelOne

Angel One Limited

Premium
Information Technology

Angel One is India's largest listed retail stockbroker and the third-largest broker by NSE active clients, behind Groww and Zerodha, with 67.55 lakh NSE active clients (14.65% share) in September 2026. Founded as a traditional, branch-and-sub-broker-led brokerage in Mumbai, it re-engineered itself between 2019 and 2022 into a mobile-first, flat-fee discount platform, and is now repositioning as a multi-product fintech platform under a Google Pay-trained Group CEO. Its franchise is skewed toward active derivatives traders from Tier-2/3 India, giving it a disproportionate 22.1% share of F&O option-premium turnover in Q2 FY27. Revenue remains broking-heavy (54.5% of Q2 FY27 gross revenue) but is diversifying into margin trade funding (interest income 35.6%), credit distribution, mutual fund distribution, wealth management, an asset management company, and a minority life-insurance joint venture. The investment debate centres on regulatory sensitivity of F&O volumes versus the earnings power of a 40-million-user platform. --- **What the company does.** Angel One provides retail and institutional broking across equity cash, equity derivatives (futures and options), currency and commodity segments on NSE, BSE and MCX; depository services as a CDSL participant; margin trading facility (MTF, branded client funding); research and advisory; distribution of third-party financial products (mutual funds, loans, insurance, fixed deposits, bonds); wealth management for affluent and high-net-worth clients (Angel One Wealth); passive asset management (Angel One Asset Management Company); and lending via its NBFC subsidiary Angel Fincap. Its presentation tagline for Q2 FY27 frames the company as "One Platform For Every Financial Journey Of India" (Q2 FY27 investor deck, 15 Oct 2026). **Company self-description (paraphrased from FY2025-26 Annual Report BRSR and press releases):** Angel One describes itself as a technology-enabled financial services platform offering investment and financial solutions through its flagship Angel One app across mobile, web and tablet, serving a pan-India client base and using AI, machine learning and data science to personalise products. **Independent characterisation.** Economically, Angel One is a high-operating-leverage transaction-processing business whose revenue is a function of (i) the number of active traders, (ii) their order frequency, especially in index options, and (iii) the balance of client funding (MTF) on which it earns a net interest spread. Fixed costs (technology, employees, brand) are large; variable costs are dominated by sub-broker (Authorised Person) commissions and exchange/clearing charges. The company is therefore exposed to market activity cycles and to SEBI rule changes affecting derivatives volumes. Management's strategic response is to convert a large, young trading-oriented user base into multi-product relationships (SIPs, wealth, credit, insurance) with annuity-like revenue. **Revenue model mix (consolidated, Q2 FY27):** Interest income has grown from 23.7% of total revenue in Q2 FY25 to 35.6% in Q2 FY27, while gross broking's share declined from roughly 60% in early FY26 to 54.5% (Q2 FY27 deck). **Customer types:** Self-directed retail traders and investors (core); active derivatives traders; first-time investors from Tier-2/3/4 towns; SIP investors; affluent/HNI clients (wealth: 2,400+ clients, June 2026); algorithmic/API traders (SmartAPI); Authorised Persons (sub-brokers) as a channel; institutional clients (institutional broking, limited scale). **Value chain position:** Retail-facing intermediary between investors and market infrastructure institutions (exchanges, clearing corporations, depositories), and increasingly a distribution layer for manufacturers (AMCs, lenders, insurers). It is moving upstream into manufacturing via its own AMC and a 26% insurance JV. **End-markets:** Indian capital markets (equity cash and derivatives, commodities), consumer credit distribution, mutual funds, wealth management, life insurance (prospective).

RevenueN/A
Employees2,942
Market CapN/A
Founded1996
United States, North America
AneriFincap

Aneri Fincap Limited

Premium
Information Technology

Aneri Fincap Limited is a three-decade-old, Mumbai-based micro-cap that was registered with the Reserve Bank of India as a non-deposit-taking NBFC whose principal activity was extending secured and unsecured loans to retail and commercial borrowers, with some securities-trading activity. Originally founded in 1990 as a leasing and hire-purchase financier, the company re-emerged in FY2016–FY2019 as an unusually leveraged lender, carrying a balance sheet above ₹1,000 Cr on a net worth of barely ₹5.6 Cr at its FY2019 peak. That book unwound rapidly between FY2020 and FY2022; heavy bad debts, according to management, then pushed the company into successive losses culminating in a ₹34.02 Cr loss in FY2024 and a negative net worth of roughly ₹44 Cr. Its shares are suspended on BSE, its RBI registration has been cancelled, and its board has dwindled to a single director. It is, in substance, a distressed corporate shell rather than an operating financial institution. --- **Company's own description (FY2023 annual report, as summarised by Groww).** The company describes itself as an RBI-registered NBFC operating in a single business segment, finance, whose principal business is lending within the regulatory framework for NBFCs. The same disclosure states that the business suffered a significant setback because of major bad debts combined with trade depression and price fluctuations, and that management therefore decided to file an application for insolvency under the Insolvency and Bankruptcy Code, 2016. Some data vendors (share.market) describe the single segment as "Lending and Securities Trading", while legacy profiles (IIFL) still describe leasing and hire-purchase services, reflecting the company's original 1990s activity. Third-party profiles (Screener, PitchBook) describe a range of secured and unsecured loans to retail and commercial clients in India. **Business model.** The economic model was a spread-lending model: the company borrowed (₹1,026.21 Cr of borrowings at FY2019 per Screener) and on-lent (other assets, principally loans and advances, of ₹1,018.43 Cr at FY2019), earning interest income. Revenue was overwhelmingly interest income; there was no product, subscription, or licensing revenue. Small investment income and trading gains/losses on securities appear episodically (investments of ₹27.02 Cr at FY2020 falling to ₹9.83 Cr at FY2023). **Revenue model mix.** **Value-chain position.** Aneri sat at the smallest, least-regulated end of India's credit chain: a base-layer NBFC that relied on wholesale borrowings (counterparties not publicly disclosed) and lent to undisclosed borrowers. It had no branch network, deposit franchise, credit rating, or co-lending partnerships that are publicly disclosed. **Customer types and end-markets.** Retail and commercial borrowers in India (Screener, PitchBook). No customer concentration, sector exposure, ticket size, or geographic distribution has been disclosed. The FY2021 Directors' Report notably stated that the company did not have an appropriate internal control system for taking unsecured loans and granting loans and advances governed by board policies, and had not appointed an internal auditor as required by Section 138(1) of the Companies Act, 2013. **Independent characterisation.** The pattern of a ₹3 Cr-equity company intermediating up to ₹1,000+ Cr of borrowings (a balance-sheet-to-equity multiple above 180x at FY2019), followed by near-total unwinding within three years, rapid board turnover, no internal auditor, and eventual write-offs, is characteristic of a thinly capitalised conduit-style NBFC rather than a franchise lender. No public evidence establishes wrongdoing, and none is alleged here; however, the structure is one that institutional diligence would treat as a high-risk governance red flag. Today the company has no lawful lending business (RBI CoR cancelled), negligible income (₹0.98 Cr in FY2024), and liabilities far exceeding assets.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1990
Mumbai, India
AnaPass

AnaPass Inc.

Premium
Information Technology

Anapass is a Seoul-based fabless designer of display system semiconductors. Its principal products are timing controllers (T-Con) for IT-class OLED panels (laptops, tablets, monitors) and T-Con-embedded drivers (TED) that integrate the timing controller with the display driver IC for mobile OLED. Its competitive edge rests on proprietary intra-panel interface technology: AiPi, developed in 2006, and UPI, a newer interface optimised for IT OLED. Management says both have been adopted as technical standards by the world's leading panel maker. Manufacturing is outsourced to foundries such as UMC. Revenue is highly concentrated in one customer ecosystem, Samsung Display, where Anapass holds a majority share in IT OLED T-Con. The company is also the strategic anchor shareholder and lender of GCT Semiconductor, a US-listed 4G/5G modem chip designer founded by the same CEO. Earnings are therefore driven by both OLED adoption in AI PCs and the risky 5G commercialisation at GCT. --- ### What the company does Anapass designs, and through foundry partners supplies, mixed-signal system-on-chip products that sit inside display panels: **Timing controllers (T-Con):** These control the timing and drive signals sent from the system to the panel's column/row drivers. Management calls the T-Con the "brain" of the display (CEO interview, thebell/Money Today, 12 Jan 2026). Today's focus is mid-size IT OLED panels for notebooks and tablets. Historically, the T-Con was used in large LCD TVs. **TED (T-Con Embedded Driver):** A single-chip combination of T-Con and display driver IC (DDI) for smartphone OLED panels. **Interface IP:** AiPi (in-house intra-panel interface, 2006) and UPI (an interface optimised for IT OLED that raises transmission speed and data efficiency). The CEO describes high-speed SerDes-type interfaces as the core of T-Con competitiveness (thebell, Jan 2026). **Services ("용역"):** Development/engineering service revenue. This was 7% of revenue in Q2 2026 (Butler). Meritz noted that service revenue in 2024 was about double a typical year. ### Company's own description Anapass describes itself as a fabless semiconductor design company founded in late 2002 on analog and digital circuit design technology. It designs chips for display products (TVs) and handsets (tablets, smartphones), with technology that helps OLED panels cut manufacturing cost and enable bezel-less designs (company recruiting statement, KAIST EE jobs board). In its January 2026 strategy interview, the company framed itself as aspiring to become a "Korean MediaTek", meaning a self-sustaining fabless supplier to global big-tech platforms. ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Model | Fabless. Design in-house, wafer fabrication outsourced to foundries such as UMC. | KIRS (Jan 2024) | | Revenue mix (product vs service) | Product sales dominate. OLED T-Con/TED was 97.8% of Q1 2026 revenue and 93% of Q2 2026 revenue, with services at 7% in Q2 2026. | Asia Economy (Jul 2026); Butler.works | | Licensing / subscription | No material licensing or subscription revenue disclosed. Interface IP is monetised through chip sales and standard adoption by the panel customer. | thebell (Jan 2026) | | Capex intensity | Low. The company states that as a fabless firm it has little need for large capex. | Dealsite (Apr 2025) | | Value-chain position | Tier-2 component supplier. Sells to panel makers (Samsung Display principally), which sell panels to device OEMs (Samsung Electronics, global notebook brands, a US portable-gaming OLED device per KIRS). Also holds compatibility certifications with platform vendors (Intel, Qualcomm, NVIDIA, AMD) as an AI PC partner. | thebell (Jan 2026); KIRS (Jan 2024); Hana via Asia Economy (Nov 2024) | | Customer types | Display panel manufacturers. Three customers each exceeded 10% of revenue in 2025–2026 ("A", "B", "C" in filings). | Asia Economy (Jul 2026) | | End-markets | Notebooks/AI PCs, tablets, monitors (IT OLED); smartphones (mobile OLED, mid-range/FE models); historically premium LCD/LED TVs | Meritz; Hana; Dealsite | ### Independent characterisation Anapass is effectively a single-ecosystem specialist. Its economics depend on (a) Samsung Display's IT OLED panel volumes, where Anapass's in-customer T-Con share has been reported at over 50% (Eugene Investment, via Dealsite) to over 70% (Hana Securities, Nov 2024), and (b) design-wins for TED in Samsung Display mobile panels, where Anapass gained share as Magnachip's share fell but has not reached flagship Galaxy S/Z models (Dealsite, May 2025). Product-mix swings between high-margin IT T-Con and lower-margin mobile TED drive large changes in revenue and margin. The group holding in GCT Semiconductor adds an option-like, cash-consuming exposure to 5G modems that has repeatedly weighed on net income.

Revenue$0.1B
Employees126
Market CapN/A
Founded2002
United States, North America
AnantRaj

Anant Raj Limited

Premium
Information Technology

Anant Raj Limited is a Delhi-NCR real estate developer in the middle of a deliberate transformation into a two-engine platform: a cash-generative, largely debt-free residential and mixed-use development business anchored on a ~220-acre integrated township (Anant Raj Estate, Sector 63A, Gurugram), and a fast-scaling digital-infrastructure business comprising colocation data centres and a sovereign/AI-ready public cloud ("Ashok Cloud"). FY26 consolidated revenue from operations was ₹2,511.6 cr (+21.9% YoY) with PAT of ₹557.0 cr (+30.8%). Data centre, infrastructure and allied services contributed ₹176.5 cr in FY26 and ₹90 cr in Q1 FY27, from 28 MW of operational IT load at Manesar and Panchkula. Management targets 63 MW by FY27, 117 MW by FY28 and 357 MW by FY32. In July 2026 the board approved a composite scheme to consolidate and demerge the data-centre/cloud business into Ashok Cloud Private Limited for separate listing, with a 1:1 share entitlement. --- ### What the company does Anant Raj Limited (ARL) operates two economically distinct businesses under one listed entity (pending demerger): **(a) Real estate and infrastructure development.** ARL develops and sells residential product in Delhi-NCR — integrated townships, plotted development, independent floors, group housing and luxury residences — and develops/operates commercial, hospitality and mixed-use assets. Its company description (as summarised by StockAnalysis/MarketScreener from filings) covers residential townships, group housing, commercial developments, IT parks, malls, office complexes, affordable housing, data centres, hospitality and serviced apartments, primarily in India and (since 2026) with a Singapore subsidiary. The flagship is Anant Raj Estate, an integrated township across ~220 acres at Sector 63A, Golf Course Extension Road, Gurugram (MarketScreener company profile). The company claims to have delivered more than 20 million sq ft across housing, commercial, IT parks, malls, hospitality and affordable housing (Screener company description) — note that Economic Times-sourced coverage of the October 2025 QIP cites 9.96 million sq ft delivered and ~320 acres of debt-free land in Delhi-NCR; the two delivered-area figures conflict and the difference is likely definitional (group-level historical vs. listed-entity recent delivery). Both are flagged. **(b) Data centres and cloud services.** Through wholly owned subsidiary Anant Raj Cloud Private Limited (ARCPL) and, increasingly, Ashok Cloud Private Limited (ACPL), the company offers colocation (powered shell and white space leased to customers), and cloud services under the "Ashok Cloud" brand (launched with Orange Business as a partner). Per the July 2026 demerger announcement, Ashok Cloud will focus on data centres, co-location, sovereign public cloud, AI-ready cloud infrastructure, disaster-recovery and data-recovery services, cloud migration and data backup (Tribune/Asianet, 21–22 July 2026, quoting the company). ### Business and revenue model | Revenue stream | Model type | Recognition characteristics | Disclosure status | |---|---|---|---| | Residential sales (plots, floors, apartments) | Product sale (development-for-sale) | Recognised largely on completion/handover under Ind AS 115; revenue lags pre-sales by 2–4 years | Pre-sales (bookings) totals for FY26 not located in sources reviewed; MOFSL projects ₹3,050 cr FY27 and ₹3,340 cr FY28 | | Revenue-share / collaboration projects | Product sale with land-owner revenue share | E.g., Destination Properties now receives 17.69% of total project revenue on a Gurugram group housing project (NSE filing, 9 April 2026) | Disclosed per-project | | Colocation data centres | Lease/service (recurring, contracted) | Monthly per-MW fees; management guided ~₹90 lakh per MW per month revenue and ~₹15 lakh per MW per month opex for co-location (Value Research, citing management, 2026) | Segment line "data centre, infrastructure and allied services" disclosed quarterly | | Cloud services (Ashok Cloud) | Subscription / usage-based IaaS & managed services | Recurring; higher revenue per MW than colocation | Not separately quantified; cloud capacity ~6 MW in FY26 rising to 36 MW by FY28 (Q2/Q3 FY26 call analyses) | | Rental / hospitality / other | Lease and service | Recurring | Bundled within "data centre, infrastructure, rental and other services" in the Annual Report | **Mix (FY26, derived):** Real estate development ≈ 93% of revenue from operations; data centre, infrastructure and allied services ≈ 7% (₹176.49 cr of ₹2,511.60 cr; Q4 FY26 investor presentation). In Q1 FY27 the data-centre line rose to ₹90 cr of ₹631.4 cr (≈14.3%; Q1 FY27 investor presentation). ### Value-chain position and customers In real estate, ARL is a land-owning developer: it holds a large legacy land bank acquired at historical cost in Delhi-NCR, obtains licences/RERA registrations, designs, markets and sells, and contracts out construction. It also monetises land through joint development (e.g., the 50:50 Avarna Projects LLP with Birla Estates, formed 2019) and revenue-share collaborations. Customers are affluent and upper-middle-income homebuyers and investors in Gurugram/Delhi, plus commercial tenants. In digital infrastructure, ARL is moving up the stack from landlord/colocation provider toward cloud services and AI-ready infrastructure. Target customers include hyperscalers and enterprises (colocation), Indian government and regulated entities (sovereign cloud), and AI/GPU workloads (via Submer/InferX collaboration). An October 2026 tri-party MoU with Orange Business Services Singapore and the Government of Haryana aims to bring overseas customers to host data in Haryana. ### Company's own description vs. independent characterisation *Company description (paraphrased from filings and press releases, 2025–26):* a five-decade Delhi-NCR real estate developer with a diversified portfolio — integrated townships, group housing, affordable housing, IT parks, malls, offices, hotels — that has also become a data-centre and cloud company through its wholly owned subsidiaries Anant Raj Cloud and Ashok Cloud. *Independent characterisation:* ARL is best understood as a land-rich, now net-cash NCR residential developer whose earnings are still >90% real estate, but whose equity valuation increasingly hinges on an unproven-at-scale data-centre platform. The real estate business is mid-cycle in harvesting its Sector 63A township; the data-centre business is early-stage (28 MW operational versus a 357 MW ambition) and capital-hungry (roadmap capex ~US$2.1 bn per QIP-period disclosures; a separate ₹25,000 cr Haryana MoU). Motilal Oswal's July 2026 note (as reported by AskFuzz) characterised ARL as a "me-too" colocation landlord within India's DC archetypes — a critical but important framing — while still valuing the DC business at ~48% of total value.

Revenue$0.3B
EmployeesN/A
Market CapN/A
Founded1969
IMT Manesar, India
AnandRayons

Anand Rayons Limited

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Anand Rayons Limited | BSE filings; MCA | | Former names / predecessor | M/s Anand Enterprise (partnership firm, est. 1 July 1987); converted to public limited company 20 September 2018 | IIFL company summary (from DRHP) | | Founding year | 1987 (partnership); incorporated as company 2018 | DRHP via IIFL; Simply Wall St | | Certificate of Incorporation | 2 October 2018 (conversion effective 20 September 2018) | DRHP via IIFL | | CIN | L51909GJ2018PLC104200 | RegisterKaro (MCA data) | | Incorporation jurisdiction | Gujarat, India; Registrar of Companies, Ahmedabad | RegisterKaro | | Registered office / HQ | 305-306, Jay Sagar Complex, Opp. Sub Jail, Surat, Gujarat 395002, India | Simply Wall St; BSE filings | | Exchange / ticker | BSE Limited — Scrip 542721, Symbol ARL (not listed on NSE) | BSE; MarketsMojo | | Listing date | July 2019 (IPO allotment 2 July 2019) | Simply Wall St; MarketsMojo capital history | | ISIN | INE02GA01012 | MarketsMojo; FinancialFilings | | LEI | 335800FAGKR4XYASNE09 | FinancialFilings | | CUSIP | Not applicable (no US listing) | — | | Face value | ₹10 per share | Screener | | Shares outstanding | ≈2.19 crore (derived: market cap ₹76.7 Cr ÷ price ₹35.0, Oct 2026); 2.147 crore reported Feb 2026 prior to July 2026 warrant conversion | Screener; Simply Wall St | | Fiscal year end | 31 March | Annual reports | | Employees | Not publicly disclosed in sources reviewed (Screener's extracted employee count is paywalled; not stated in aggregator data) | — | | Statutory auditor | M/s M. R. Bombaywala & Co., Chartered Accountants (unmodified opinion on FY2026 results) | FY2026 results (BSE, 22 May 2026) | | Internal auditor | M/s Sutarwala & Associates, Chartered Accountants, Surat (re-appointed for FY2027) | FY2026 board outcome | | Company Secretary & Compliance Officer | Mrs. Varsha Maheshwari | BSE filings (2023–2026) | | Market capitalisation (current) | ≈₹76.7 Cr at ₹35.0 (15 Oct 2026) | Screener | | Website | www.anandrayons.com | Company | | Industry classification | Consumer Discretionary › Textiles › Textiles & Apparels › Trading – Textile Products; NIC 51909 (wholesale trade) | Screener; RegisterKaro | The listing details supplied (Country: India; Exchange: BSE; Ticker: ARL.BO) correspond to Anand Rayons Limited, BSE scrip code 542721, BSE trading symbol ARL, Reuters RIC ANAY.BO. The entity has not changed its name since conversion to a company in 2018 and remains listed on BSE. Anand Rayons Limited is a Surat-based, promoter-controlled trader and distributor of synthetic and value-added yarns — principally polyester, nylon, viscose, embroidery and dyed yarns, and zari/core yarns — serving weavers, embroiderers, zari manufacturers and garment converters concentrated in Gujarat's synthetic-textile cluster and other Indian textile hubs. Operating since 1987 as a dealership-led wholesaler that historically represented mills such as JCT, Indorama Synthetics, Garden Silk and Filatex (Philatex), the company runs an asset-light, working-capital-intensive model with gross margins near 4% and operating margins of roughly 2–2.5%. FY2026 revenue reached a record ₹433 Cr with net profit of ₹7.25 Cr, funded in part by a ₹54 Cr preferential-warrant equity raise that de-levered the balance sheet. Management has signalled diversification into petrochemical oils, aluminium-foil packaging and food, but the business remains effectively a single-segment domestic textile trading house. Its equity has fallen ~92% from its ₹470 peak despite rising earnings. --- ### What the company does Anand Rayons is a trading and distribution business in man-made fibre (MMF) yarns. It purchases yarn in bulk from spinning/polymerisation mills (historically as an authorised dealer) and resells to downstream textile units — weavers producing sarees, shirting and dress material; embroidery units; yarn dyers; zari (metallic thread) manufacturers; carpet makers; narrow-fabric/elastic-tape producers; and sizing units. The company's own historical description (from its 2019 DRHP, as summarised by IIFL) emphasises trading in value-added yarns such as doped-dyed yarns and fancy yarns, a strong market share in embroidery and dyed yarn locally, and the supply of core yarn in value-added form to zari manufacturers. The company's filings classify it in a single reportable segment — textiles/trading. The Q1 FY2026 results described the trading division as constituting the entirety of operations (ScanX digest of BSE filing, August 2025), and the Q2 FY2026 results reiterated that the company operates solely in the textile segment. ### Company's own characterisation (latest available) The company's annual-report business overview (FY2024 report, as extracted by Screener) describes Anand Rayons as part of the "Anand Group", specialising in embroidery yarn, dyed yarn, and fabric manufacturing for T-shirts, garments and apparel. The same report states the company had diversified into petrochemical products — yellow oil, white oil, base oil and palm oil, primarily for adhesive industries — planned to export chemicals internationally, and had ventured into packaging by importing aluminium foil and other packaging products. Screener's corporate summary describes the business as "manufacturing and trading of yarn & fabrics", though no manufacturing fixed assets of consequence appear on the balance sheet (fixed assets ≈₹1 Cr at March 2026), which suggests any "manufacturing" is outsourced/job-work based. ### Business model and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Product vs. service mix | ~100% product sales (traded goods); no disclosed service, subscription or licensing revenue | Single trading segment in results | | Value-chain position | Mid-stream intermediary between yarn producers (polymer/spinning mills) and fragmented downstream weaving/embroidery/zari units | DRHP history; AR FY2024 | | Gross margin | ≈4.7% (Simply Wall St TTM gross profit ₹18.8 Cr on revenue ₹401 Cr, data to Dec 2025) | Simply Wall St | | Operating margin (OPM) | 1.4%–2.5% range across FY2020–FY2026 | Screener | | Capital intensity | Very low fixed assets (≈₹1 Cr); balance sheet is >95% current assets (receivables, inventory, cash) | Screener balance sheet | | Working-capital profile | Debtor days 73, inventory days 7, payable days 3 → cash conversion cycle 77 days (FY2026) | Screener ratios | | Credit role | Effectively extends trade credit to small downstream units while paying suppliers quickly — a financing function embedded in the trading margin | Debtor vs payable days | | Customer types | MSME weavers, embroiderers, zari makers, yarn dyers, carpet and elastic-tape makers, sizing units | DRHP via IIFL | | End-markets | Domestic Indian apparel, ethnic wear (sarees, dress material), home textiles (carpets), narrow fabrics | DRHP via IIFL; Zonebourse description | | Geography | Domestic India only; historically Surat, later Ahmedabad, Vapi, Daman, Varanasi, Ichalkaranji, Bengaluru, Erode, Coimbatore | DRHP via IIFL | ### Independent characterisation In substance, Anand Rayons is a thin-margin, high-turnover working-capital business whose economic value derives from (a) supplier relationships and dealership access in a commoditised market, (b) credit underwriting of small textile units, and (c) inventory/price-risk management in yarns whose prices track crude-oil-linked feedstocks (PTA, MEG, caprolactam). Return on equity has historically been modest (5-year average ≈8% per Screener) because each rupee of profit requires substantial receivables financing. The FY2025–FY2026 preferential equity raise transformed the balance sheet from a 1:1 debt-to-equity structure to ~0.35x and enabled the 38% revenue jump in FY2026, but it also diluted ROE. The announced diversification initiatives (petrochemical oils, aluminium foil, food partnership) have not been reported as separate segments, and their revenue contribution is not publicly disclosed.

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1987
Surat, India
Amraworld

Amraworld Agrico Limited

Premium
Information Technology

Amraworld Agrico Limited is an Ahmedabad-registered, BSE-listed micro-cap that today functions as a dormant investment-holding shell rather than an operating enterprise. Its memorandum permits own-account and client trading, broking, arbitrage and hedging across agricultural produce, metals, precious stones, energy products, commodities and securities, and it historically traded castor seeds from FY2007. In practice, the company has reported revenue from operations in only two of the last eleven fiscal years (INR 1.44 crore in FY2019 and INR 1.99 crore in FY2022) and none since FY2023. Its INR 12.85 crore balance sheet is almost entirely investments, whose valuation swings drive reported profits and losses. With no promoter, no debt, no fixed assets, rapidly rotating directors, repeatedly changing website domains, and roughly 44,600 retail shareholders, the stock trades below book value at about INR 6 crore. It is best characterised as a governance-risk-heavy listed shell whose equity value rests on an opaque investment book. --- ### The company's own description The FY2025 Directors' Report (33rd Annual Report) is unusually candid. In its "Operations Review" it states that, owing to sluggish market conditions, the company did not generate any revenue from operations during the year, but earned some other income and, after fixed expenses, posted a net profit of INR 25,49,818. Under "State of the Company's Affairs" it states that the company does not have any significant business activity and did not carry out any business during the year under review. Data vendor Value Research summarises the position in one line: the company does not have significant operations. The objects clause, as summarised from the FY2022 annual report by Screener, permits own-account and client trading, broking, market-making, arbitrage and hedging across agricultural products, metals, stones and diamonds, energy products, commodities and securities. ROIC.ai's vendor description similarly lists trading in agricultural products, metals, shares, securities, debentures, precious metals, precious stones, diamonds, petroleum and energy products in spot, futures and derivative markets. Older broker descriptions (Business Standard, Kotak) describe the company as trading in shares, securities, debentures and other investments, and note that it started trading castor seeds in 2006-07. ### Independent characterisation Analytically, Amraworld Agrico should be viewed as a listed holding vehicle with three observable characteristics: 1. **No operating engine.** Revenue from operations was nil in FY2015–FY2018, FY2020–FY2021 and FY2023–FY2026. The two revenue years (FY2019: INR 1.44 crore; FY2022: INR 1.99 crore) were trading turnover at thin margins. Screener notes a contradiction in FY2022: the accounts reported INR 1.99 crore of sales and INR 1.56 crore of purchases while the Directors' Report simultaneously said there was no operating revenue or business. 2. **An investment book is the entire enterprise.** Investments were INR 12.83 crore out of INR 12.85 crore total assets at 31 March 2026 (99.8%). Profit and loss outcomes are driven by "other income," which has ranged from +INR 2.80 crore to –INR 4.54 crore in a single quarter. 3. **Governance characteristics typical of a shell.** Zero promoter holding, no remuneration to directors, director tenures measured in months, a 27-year-old whole-time director/CFO with three years of experience (appointed August 2025), and a second WTD/CFO appointment within about 13 months (September 2026). ### Business and revenue model | Dimension | Assessment | |---|---| | Business model | Dormant trading company / investment holding | | Revenue model mix | Product trading 100% of operating revenue in the years it existed (FY2019, FY2022); services, subscription, licensing: nil | | Value-chain position | Historically an intermediary trader (no manufacturing, processing, storage or logistics assets disclosed) | | Customer types | Not publicly disclosed | | End-markets | Historically agricultural commodities (castor seed) and securities; currently none operational | | Recurring income | None from operations; other income (investment-related) is non-recurring and volatile | ### Caution on third-party descriptions Several aggregator websites carry generic, apparently auto-generated descriptions claiming that the company runs supplier networks, logistics infrastructure, quality assurance, cultivation, processing and "advanced agricultural technologies" (for example, FinancialFilings.com and StockAlarm). These descriptions are inconsistent with the company's own Directors' Report and with its reported financials (zero fixed assets, zero revenue). They should be disregarded.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1991
Ahmedabad, India
Amradeep

Amradeep Industries Limited

Premium
Information Technology

Amerise Biosciences Limited is a 42-year-old BSE-listed Gujarat company that began life as Amstar Laminates. It drifted through laminates, commodity trading and castor-seed trading as Amradeep Industries, and was renamed in 2021 to signal a move into "biosciences". In practice the listed entity has had no meaningful operations for most of the past decade. Revenue was zero in most years. The one exception was a single INR 9.58 crore trading year in FY2026's predecessor period, FY2022. The balance sheet holds about INR 7.4 crore of total assets, mostly investments and other current assets, with no debt and no fixed assets. Net worth of about INR 5.4 crore roughly matches the market value. The company has no identified promoter, a retail-dominated register of about 33,000 holders, and frequent changes to its key managerial personnel and website domains. Some aggregators link it to Amerise Pharmaceuticals Pvt Ltd, an Ahmedabad pharmaceutical development firm, but no filed corporate relationship has been verified. The investment case rests on corporate action, not on operations. --- **What the company does today.** On the evidence available, the listed company does not run an identifiable operating business: - Tickertape describes it as currently inactive with no revenue generation. - Kotak Neo's profile, drawing on the company's disclosures, says that in FY2025 the company carried out no business activities because of a "financial crisis". - Screener's legacy profile describes it as non-operational for several years. **Company's own description.** Exchange and broker profiles, which derive from company filings, describe the history as follows. The company was incorporated in 1984 as Amstar Laminates, described as a maker of construction and agricultural equipment. It was renamed Amradeep/Amardeep Industries on 29 October 2002 and Amerise Biosciences in 2021. It was originally engaged in commodity trading and added castor-seed trading in FY2007. The 2009–10 annual report on BSE refers to the castor-seed trading environment in Gujarat, which is consistent with this history. The description of "construction and agricultural equipment" manufacturing is inconsistent with the "Laminates" name and with Screener's description of decorative boards and laminate sheets. Both versions circulate in aggregator databases, and the discrepancy is unresolved in the sources reviewed. That is the website of Amerise Pharmaceuticals Pvt Ltd, a private company established in 2018. It focuses on NDA, 505(b)(2) and complex formulations (injectables, ophthalmics, oral dosage forms) and has offices in Cranbury (New Jersey, USA), Buckshaw Village (Lancashire, UK) and Bodakdev (Ahmedabad, India). The listed company reports no subsidiaries in available data, and its balance sheet carries no fixed assets, laboratories or R&D spend. It may be a naming coincidence or an aggregator misattribution, or it may signal an intended but undisclosed relationship. **Business model and revenue model.** No recurring revenue model exists. Screener's quarterly data show small "sales" in each quarter of FY2026 (0.06, 0.07, 0.04 and 0.08), which sum to about INR 0.25 crore. The annual statement instead books about INR 0.26 crore as other income and zero as sales. This is a classification discrepancy between quarterly and annual presentation. Either way, the income most likely reflects interest or financing income on loans and advances, not trading. **Value-chain position, customers and end-markets.** Not applicable or not publicly disclosed. Data vendors classify the company in very different industries: - Plastic Products – Industrial (Screener, MarketsMojo) - Finance – Investment (StockEdge, MoneyWorks4Me) - Other Agricultural Products (Research360) - Pharmaceuticals (Emkay) - Blank-check company (MarketScreener) This spread is itself diagnostic of an entity without a defined business. **Independent characterisation.** Amerise Biosciences is best described as a listed shell with a small treasury of investments and loans. It is funded entirely by legacy equity of INR 6.61 crore, with accumulated losses of about INR 1.2 crore. Its main economic asset is its BSE listing and a large, fragmented retail shareholder base. The FY2022 burst of INR 9.58 crore of trading revenue coincided with an 84-fold rise in shareholder count, and the 2021 rename to "biosciences" came without any disclosed pharmaceutical assets. Taken together, these show a listed vehicle whose narrative has shifted without the operations to support it.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1984
Gandhinagar, India
AMJLand

AMJ Land Holdings Limited

Premium
Information Technology

AMJ Land Holdings is a Pune-based, promoter-controlled micro-cap that evolved from one of western India's oldest specialty-paper manufacturers into a land-bank monetisation vehicle. After hiving off its paper business to Pudumjee Paper Products in February 2016, the company retained surplus industrial land at Thergaon (Pimpri-Chinchwad) and now earns from three streams: residential/commercial development through a 95%-owned partnership, AMJ Land Developers (flagship "GREENS", ~1 million sq ft, 96% sold as of AR FY25); leave-and-license income from ~29 acres let to group company Pudumjee Paper Products; and a small 4.6 MW wind portfolio in Satara and Sangli. It is debt-free with roughly INR 109 Cr of cash and short-term investments at March 2026 against a market value of ~INR 147 Cr, trading at about 0.7x book. Its investment case therefore hinges on the next land-development cycle (GREEN VILLE, AMJ Realty redevelopment), capital allocation discipline — notably related-party lending — and the Jatia family's governance stewardship. --- ### Company's own description In its FY2025 annual report the company describes itself as focused on real estate development and renewable energy, anchored by the GREENS project in Pune and wind plants in Maharashtra, and frames its mission around sustainable, community-oriented residential and commercial spaces [AR FY25, front section]. Screener's summary of the annual report characterises the business as real estate development, leasing of real estate, wind power and investments [Screener "About", citing AR FY23 p.134]. Brokerage profiles similarly describe it as engaged in leasing of real estate, wind power, and real-estate development through subsidiaries. ### Independent characterisation Economically, AMJ is a land-rich holding company with four value pools: 1. **Real estate development (≈90%+ of consolidated operating revenue).** Conducted through AMJ Land Developers (ALD), a partnership firm in which AMJ holds a 95% stake, consolidated as a "subsidiary entity" [AR FY25 Annexure-1]. ALD's FY2025 revenue was INR 7,369.71 lakh (FY2024: INR 5,268.44 lakh) [AR FY25 Directors' Report]. Revenue is recognised on project completion/handover (Ind AS 115), producing lumpy, tower-by-tower earnings. 2. **Leasing of real estate.** A leave-and-license of ~29 acres at Thergaon to Pudumjee Paper Products Ltd (PPPL) yielded INR 148.68 lakh (incl. GST) in FY2025, plus INR 10.89 lakh for a portion of Jatia Chambers, Mumbai [AR FY25 Annexure-5, AOC-2]. The Thergaon agreement ran 1 Feb 2021 – 31 Jan 2026 and its renewal was approved via postal ballot on 30 Jan 2026. 3. **Wind power generation.** Three turbines (2 × 1.25 MW at Sadawaghapur, Satara; 1 × 2.1 MW at Jath, Sangli) totalling 4.6 MW, selling power under open access [AR FY25]. FY2026 segment revenue was INR 227.52 lakh [Res Q1FY27 segment note]. 4. **Treasury and strategic investments.** Liquid mutual funds (e.g., Nippon India Liquid Fund INR 17.65 Cr, HSBC Liquid Fund INR 11.85 Cr at 31 Mar 2025 [AR FY25 Annexure-4]), equity holdings marked through OCI, and associate stakes in 3P Land Holdings (27.24%) and Biodegradable Products India Ltd (27.11%). Inter-corporate deposits (ICDs) to related parties are a material use of capital. ### Revenue model mix | Revenue stream | Model | Nature | Approx. share of FY2026 consolidated operating revenue | |---|---|---|---| | Residential/commercial sales (GREENS) | Product (completed-contract recognition) | Lumpy, cyclical | ~90%+ (derived) | | Leave & license (land, office) | Service / rental | Annuity-like, related-party | Small single-digit % | | Wind power sale | Product (energy) | Weather-dependent | ~4% (227.52 lakh of ~5,250.6 lakh) | | Interest, MF gains, dividends | Other income | Treasury | Reported as other income (~INR 10 Cr FY26 per Screener) | There is no subscription or licensing revenue. ### Value chain position and customers AMJ sits at the landowner-developer end of the value chain: it owns the land (historically industrial), obtains approvals, and develops via ALD, outsourcing construction. Customers are retail homebuyers in Pimpri-Chinchwad (mid-to-upper segment 2/3/4 BHK), a small number of commercial unit buyers, one related-party industrial licensee (PPPL), and open-access power consumers/the grid. End-markets: Pune residential real estate, Maharashtra power market.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1964
Pune, India

Page 214 of 482

1…213214215…482

Page 214 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo